Pyrazolotriazine Derivatives Useful as CDK9 Inhibitors

Non-covalent pyrazolotriazine derivatives address the limitations of existing CDK9 and CDK2 inhibitors by providing selective and potent inhibition, improving treatment options for cancers, viral infections, and inflammatory diseases.

JP2024541474APending Publication Date: 2024-11-08ORIGENIS
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024531015
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-23
Filing Date
2022-11-21
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing CDK9 and CDK2 inhibitors, such as those described in WO2016/160617A2, suffer from drawbacks including covalent enzyme inhibition and lack of selectivity, which limits their efficacy and drug discovery potential.

Method used

Development of non-covalent pyrazolotriazine derivatives that selectively inhibit CDK9 and/or CDK2, offering improved selectivity, low toxicity, and better drug metabolism properties.

Benefits of technology

The pyrazolotriazine derivatives provide potent inhibition of CDK9 and CDK2, enhancing therapeutic potential for treating cancers, viral infections, and inflammatory diseases by targeting these kinases effectively.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541474000001_ABST
    Figure 2024541474000001_ABST
Patent Text Reader

Abstract

The present invention relates to novel compounds of formula (I), which are inhibitors of CDK2 and / or CDK9 and are useful in the treatment of a variety of diseases, including hyperproliferative diseases, virally induced infections, and cardiovascular diseases. [Formula 1] JPEG2024541474000050.jpg122168
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of biomedicine, specifically, to a series of novel inhibitors of cyclin-dependent kinases having a pyrazolotriazine structure and their uses. The present invention includes the use of compounds, pharma- ceutically acceptable salts, solvates of said compounds or prodrugs, and pharmaceutical compositions of said compounds as inhibitors of cyclin-dependent kinases. [Background technology]

[0002] Cyclin-dependent kinases (CDKs) are members of the serine / threonine kinase family that exert their catalytic function by forming heterodimers with regulatory subunits cyclins. Members of the CDK family can be classified into cyclic CDKs and transcriptional CDKs according to their different functions. The former include CDK1 / 2 / 4 / 6, which mainly control the cell cycle process; the latter include CDK7 / 8 / 9, which mainly regulate the transcription and processing of mRNA (Malumbres M. et al., Genome Biol., 2014, 15:122). Overexpression or enhanced function of transcriptional CDKs causes a significant increase in the expression of certain downstream genes, especially the anti-apoptotic protein Mcl-1, which leads to tumors (Morales F. et al., Cell Cycle, 2016, 15:519). Recently, it has been discovered that non-selective CDK inhibitors can achieve anti-tumor effects by inhibiting the function of CDK9 and / or CDK2. Therefore, research on CDK inhibitors has attracted people's attention (Krystof V. et al., Target, Curr. Pharm. Des., 2012, 18:2883-2890). Research has revealed that overexpression of CDK9 is associated with the development of various tumors, inflammation and viral replication, such as acute myeloid leukemia, breast cancer, colon cancer and prostate cancer, as well as human immunodeficiency virus and adenovirus (Franco LC. et al., J. Cell Biochem., 2017, 119:1273-1284). These findings indicate that CDK9 is an effective target for cancer treatment. CDK9 inhibitors introduced into clinical practice include flavopiridol, dinaciclib, SNS-032 and CYC065, all of which lack selectivity for CDK9 or CDK2. Some CDK9 selective inhibitors are currently in preclinical studies, such as LY2857785, LDC000067, while others are in clinical stages, such as KB-0742 in Phase I / II, enitsilib (VIP152 or BAY-1251152) in Phase I / II, and atubeciclib (BAY-1143572) in Phase I.Fadracilib (CMY065) is a clinical-stage CDK9 inhibitor for anticancer applications that benefits from its additional CDK2 activity (Frame S. et al., PLos ONE, 2020, 15(7):e0234103). Pharmacological inactivation of CDK2 can inhibit MYC-driven tumorigenesis. Further studies have shown that CDK2 is also required for viral replication. Thus, inhibiting CDK2 suppresses viral replication of cytomegalovirus: Bresnahan WA et al., VIROLOGY 231, 239-247 (1997); Adenovirus: Cheng P-H. et al., PLoS One 8, e57340.; Influenza A virus: Martinez Gil L. et al., Antiviral Research, Vol. 100, No. 1, October 2013, pp. 29-37; Zika virus: Xu M., Nat Med 2016;22:1101-1107. Recently, the role of CDK2 in neutrophil inflammation has been studied, and it has been shown that inhibition of CDK2 inhibition significantly improves the outcome of lethal systemic inflammation (Hsu AY. et al., PNAS,10,2019, Vol. 116, no. 37, 18561-18570). Therefore, synergistic inhibition of CDK9 and CDK2 may be beneficial for treating both cancer and viral infections and inflammation.

[0003] Pyrazolotriazines as inhibitors of CDKs, including CDK9, are disclosed in WO2016 / 160617A2. However, the inhibitors disclosed therein have various drawbacks. All compounds outlined in Table A1 of WO2016 / 160617A2 contain an acrylamide or an acrylamide moiety. Furthermore, paragraph

[0462] of this document teaches that covalent inhibition is a necessary feature of the invention disclosed therein. The acrylamide moiety is an inherent feature of covalent enzyme inhibition, which is known to have several drawbacks (Sutanto et al., SC Med.Chem., 2020, 11, 876). WO2016 / 160617A2 does not teach how to arrive at non-covalent inhibition of CDK9 or CDK2. WO2016 / 160617A2 teaches that at least one amide bond is necessary for the invention disclosed therein. R 1 are disclosed in two examples (Y7 and Y8) in which is linked to the bicyclic core via a C-C bond, but for these compounds no biological activity against any CDK is reported in WO2016 / 160617A2, and thus the document does not teach or indirectly suggest that such modifications enhance potency against CDK9 and / or CDK2. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] WO2016 / 160617A2 [Non-patent literature]

[0005] [Non-Patent Document 1] Malumbres M. et al., Genome Biol., 2014, 15:122 [Non-Patent Document 2] Morales F. et al., Cell Cycle, 2016, 15:519 [Non-Patent Document 3] Krystof V. et al., Target, Curr. Pharm. Des., 2012, 18:2883-2890 [Non-Patent Document 4] Franco L.C. et al., J. Cell Biochem., 2017, 119:1273-1284 [Non-Patent Document 5] Frame S. et al., PLos ONE, 2020, 15(7):e0234103 [Non-Patent Document 6] Bresnahan WA et al., VIROLOGY 231, 239-247 (1997) [Non-Patent Document 7] Adenovirus: Cheng P-H. et al., PLoS One 8, e57340. [Non-Patent Document 8] Influenza A virus: Martinez Gil L. et al., Antiviral Research, Vol. 100, No. 1, October 2013, pp. 29-37 [Non-Patent Document 9] Zika virus:Xu M., Nat Med 2016;22:1101-1107 [Non-Patent Document 10] Hsu AY. et al., PNAS, 10, 2019, vol. 116, no. 37, 18561-18570 [Non-Patent Document 11] Sutanto et al., SC Med. Chem., 2020, 11, 876 Summary of the Invention [Problem to be solved by the invention]

[0006] The object of the present invention is to overcome the limitations of WO2016 / 160617A2 by providing potent non-covalent inhibitors of CDK9 and CDK2 without the need for acryl warheads.

[0007] Therefore, the object of the present invention was to provide novel inhibitors of CDK2 and / or CDK9 that overcome the shortcomings of the compounds of the prior art. In particular, it was an object to increase the selectivity for CDK2 and / or CDK9 and improve the druggability. The main object of the present invention was to provide a group of CDK2 and / or CDK9 small molecule inhibitors that show high efficiency, low toxicity, and excellent drug metabolism properties and can be used for the prevention and / or treatment of diseases. This object has been solved by the compounds of the present invention. The present invention provides CDK2 and / or CDK9 small molecule inhibitors containing a pyrazolotriazine structure. [Means for solving the problem]

[0008] The present invention provides one or more compounds of formula (I), or a salt thereof:

[0009] [ka] {In the formula, R 1 is an alkyl group, an alkenyl group, an alkynyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkylcycloalkyl group, a heteroalkylcycloalkyl group, an aryl group, a heteroaryl group, an aralkyl group, or a heteroaralkyl group; all of these groups may be optionally substituted; R 2 is selected from the following groups:

[0010] [ka] (In the formula, X is a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; X1 is a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, or heteroalkylcycloalkyl group; Y is a halogen atom, CN, OH, NH2, N3; or a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, aryl, or aralkyl group; or a carbon or nitrogen atom of an optionally substituted heterocycloalkyl or heteroaryl group; or a carbon, nitrogen, oxygen, or sulfur atom of an optionally substituted heteroalkyl, heteroalkylcycloalkyl, or heteroaralkyl group; Y1 is an oxygen atom, a sulfur atom, NH; or a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, or alkylcycloalkyl group; or a carbon or nitrogen atom of an optionally substituted heteroalkyl or heteroalkylcycloalkyl group; Z and Z2 are carbon atoms of an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, aryl or aralkyl group; or carbon or nitrogen atoms of an optionally substituted heterocycloalkyl or heteroaryl group; or carbon, nitrogen, oxygen or sulfur atoms of an optionally substituted heteroalkyl, heteroalkylcycloalkyl or heteroaralkyl group; Z1 is a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, or alkylcycloalkyl group; or a carbon or nitrogen atom of an optionally substituted heteroalkyl or heteroalkylcycloalkyl group; or X and Z, or X and Z1, or X and Z2, or X1 and Z, or X1 and Z1 are both part of a ring of a cycloalkyl or heterocycloalkyl group, or X and Z, or X1 and Z1 are both part of a ring of an aryl or heteroaryl group; where X is a carbon atom, X1 is a carbon atom, Z is a carbon, nitrogen, oxygen or sulfur atom, Z1 is a carbon or nitrogen atom, and Z2 is a carbon, nitrogen, oxygen or sulfur atom;

[0011] R 3 is a hydrogen atom, a halogen atom, a CN group, or an alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; all of which groups may be optionally substituted; and R 4 is a hydrogen atom, a halogen atom, a CN group, or an alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; all of which groups may be optionally substituted; or R 3 and R 4 together form a fused cycloalkyl group, heterocycloalkyl group, aryl group, or heteroaryl group; all of which groups may be optionally substituted.

[0012] Preferably, R 4 is a hydrogen atom, a halogen atom, C 1~4 Alkyl group or C 3~5 It is a cycloalkyl group. More preferably, R 4 is a hydrogen atom, a methyl group, or a cyclopropyl group. Most preferably, R 4 is hydrogen.

[0013] Preferably, R 3 is a hydrogen atom, halogen atom, CN, C 1~4 Alkyl group, C 1~4 It is a heteroalkyl group, or an optionally substituted phenyl group. More preferably, R 3 is hydrogen, Cl, Br, CF3, CN, a methyl group, an ethyl group, an isopropyl group, or a phenyl group. Most preferably, R 3 is hydrogen, Cl, Br, CF3, CN or a methyl group. More preferably, R 3 and R 4 Both have the formula -(CH2) n -group, where n is 3 or 4 (especially 3). More preferably, R 3 is Cl, and R 4 is hydrogen.

[0014] Preferably, R 2 is selected from the following group:

[0015] [ka] (In the formula, X and Z, or X and Z1, or X and Z2, or X1 and Z, or X1 and Z1 are both part of a ring of a cycloalkyl group or a heterocycloalkyl group, or X and Z, or X1 and Z1 are both part of a ring of an aryl group or a heteroaryl group; where X is a carbon atom, X1 is a carbon atom, Z is a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom, Z1 is a carbon atom or a nitrogen atom, and Z2 is a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom.

[0016] More preferably, R 2 is selected from the following group:

[0017] [ka] (wherein X and Z are both part of a ring of an aryl or heteroaryl group; where X is a carbon atom and Z is a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom).

[0018] More preferably, R 2 is selected from the following group:

[0019] [ka] (wherein X1 and Z1 are both part of a ring of an aryl or heteroaryl group; where X1 is a carbon atom and Z1 is a carbon atom or a nitrogen atom).

[0020] Particularly preferably, Y is a halogen atom (especially F or Cl).

[0021] More preferably, R 2 is a phenyl group which has one substituent in the ortho position and which is optionally further substituted; or a heteroaryl group containing 5 or 6 ring atoms independently selected from C, N, O and S, which heteroaryl group has one substituent in the ortho position and which is optionally further substituted. More preferably, R 2 is an optionally further substituted phenyl group having one substituent in the ortho position. More preferably, R 2 is a phenyl group bearing one substituent at the ortho position and optionally further substituted with one or two substituents; where the substituents are independently selected from F, Cl, Br and Me. More preferably, R 2 is a phenyl group substituted at the 2- and 6-positions (i.e., a phenyl group with two ortho substituents); where the substituents are preferably independently selected from F and Cl. More preferably, R 2 is selected from the following group:

[0022] [ka]

[0023] Most preferably, R 2 is a 2,6-difluorophenyl group. Preferably, R 1 is an arbitrarily substituted C 3~7 a cycloalkyl group, an optionally substituted heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N, and O, an optionally substituted phenyl group, an optionally substituted benzyl group, an optionally substituted heteroaryl group containing 5 or 6 ring atoms independently selected from C, N, O, and S, or an optionally substituted heteroalkyl group containing 1 to 12 carbon atoms and 1 to 6 heteroatoms independently selected from N, O, and S. More preferably, R 1 is an arbitrarily substituted C 4~6 It is a cycloalkyl group, an optionally substituted phenyl group, or an optionally substituted pyrazol-4-yl group. More preferably, R 1 is selected from the following group:

[0024] [ka] (In the formula, R 5 is the -NH group, C 1~6 a heteroalkyl group, or a heterocycloalkyl group containing 5 or 6 ring atoms independently selected from C, N, and O.

[0025] Preferably, R 5is selected from the following groups: -NH2, -NMe2, pyrrolidinyl, piperidinyl, morpholinyl, -NH(CH2)2F, -NH(CH2)3F, -NH(CH2)2OH, -NH(CH2)3OH, -NH(CH2)2OMe, -NH(CH2)3OMe, -N(Me)(CH2)2F, -N(Me)(CH2)3F, -N(Me)(CH2)2OH, -N(Me)(CH2)3OH, -N(Me)(CH2)2OMe, and -N(Me)(CH2)3OMe. More preferably, R 1 has the following structure:

[0026] [ka] (In the formula, R 6a is hydrogen, halogen or C 1~4 Heteroalkyl groups (especially -OC 1~4 alkyl group); R 6b is hydrogen, halogen or C 1~4 Heteroalkyl groups (especially -OC 1~4 alkyl group), and R 6 is C 1~6 Alkyl group, C 1~6 Heteroalkyl groups, optionally substituted C 3~7 a cycloalkyl group or a heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N, and O and optionally substituted.

[0027] Preferably, R 6a is hydrogen, Cl or OMe. More preferably, R 6b is hydrogen. More preferably, R 6 is a methyl group, a group of formula -C(CH3)2CN, an optionally substituted cyclohexyl group, an optionally substituted piperidinyl group, or a tetrahydropyranyl group. More preferably, R 6 is the formula -Cy-LR 6c where Cy is an optionally substituted C 3~7is a cycloalkylene group or an optionally substituted heterocycloalkylene group containing 3 to 7 ring atoms independently selected from C, N, and O; L is a bond or a CH group; R 6c is an arbitrarily substituted C 3~7 It is a cycloalkyl group or a heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N and O, which is optionally substituted. More preferably, Cy is a cyclohexylene group or a piperidinylene group. More preferably, R 6c is a cyclopropyl group or a heterocycloalkyl group containing 4 to 6 ring atoms independently selected from C, N, and O, which is optionally substituted. More preferably, R 1 has the following structure:

[0028] [ka] (In the formula, R 7a is hydrogen, halogen, CN or -OC 1~4 R is an alkyl group; 7b is hydrogen, halogen, CN or -OC 1~4 is an alkyl group, R 7 is C 1~6 a heteroalkyl group, an optionally substituted heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N, and O, or an optionally substituted heteroalkylcycloalkyl group containing 4 to 12 atoms independently selected from C, N, and O.

[0029] Preferably, R 7b is hydrogen or a methoxy group; preferably hydrogen. More preferably, R 7a is hydrogen, fluorine, CN or -OC 1~4 It is an alkyl group; preferably it is hydrogen. More preferably, R 7is an optionally substituted piperazinyl group, an optionally substituted piperidinyl group, an optionally substituted morpholinyl group, or an optionally substituted tetrahydropyridinyl group. More preferably, R 7 is of the formula -Cy'-L'-R 7c where Cy′ is an optionally substituted C 3~7 is a cycloalkylene group or an optionally substituted heterocycloalkylene group containing 3 to 7 ring atoms independently selected from C, N, and O; L' is a bond or a CH group; R 7c is an arbitrarily substituted C 3~7 It is a cycloalkyl group or a heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N and O, which is optionally substituted. More preferably, R 7 is represented by the formula -CO-R 7d or -CO-NH-R 7d where R 7d is C 1~4 It is an alkyl group or a heterocycloalkylene group containing 3 to 7 ring atoms independently selected from C, N and O and which is optionally substituted.

[0030] According to a further embodiment, the present invention relates to a compound of formula (II):

[0031] [ka] (In the formula, R 2 , R 3 and R 4 is as defined above.) The compound of formula (II) is an intermediate for the preparation of the compound of formula (I).

[0032] The most preferred compounds of the present invention are the compounds disclosed in the Examples, or salts thereof. It is further preferred to combine the preferred embodiments of the present invention in any desired manner (e.g., R 1 Any embodiment of2 (may be combined with any embodiment of

[0033] According to a further preferred embodiment, the following compounds are excluded from the scope of the present application:

[0034] [ka]

[0035] The present invention further provides a method for the synthesis of a compound of formula (II), which method comprises reacting a compound of formula (III) with methyl thiocyanate, i.e. a compound of formula H3C-SC≡N.

[0036] [ka] (In the formula, R 2 , R 3 , and R 4 is as defined above)

[0037] Preferably, the synthesis is carried out in the presence of trifluoromethanesulfonic anhydride (Tf2O) and 2-chloropyridine in a solvent such as dichloromethane. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0038] The term alkyl refers to a saturated, straight or branched chain hydrocarbon group containing 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, in particular 1 to 6 (e.g. 1, 2, 3 or 4) carbon atoms, such as, for example, methyl (Me, CH3), ethyl (Et), n-propyl (nPr), isopropyl (iPr), n-butyl (nBu), isobutyl (iBu), sec-butyl (sBu), tert-butyl (tBu), n-pentyl, isopentyl, n-hexyl, 2,2-dimethylbutyl or n-octyl groups.

[0039] C 1~6 The term alkyl refers to a saturated straight or branched chain hydrocarbon group containing 1 to 6 carbon atoms.1~4 The term alkyl refers to saturated straight or branched chain hydrocarbon groups containing 1 to 4 carbon atoms. Examples are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl groups.

[0040] The expressions alkenyl and alkynyl refer to at least partially unsaturated linear or branched hydrocarbon groups containing 2 to 20 carbon atoms, preferably 2 to 15 carbon atoms, in particular 2 to 10 (e.g. 2, 3 or 4) carbon atoms, such as the ethenyl (vinyl), propenyl (allyl), isopropenyl, butenyl, ethynyl (acetylenyl), propynyl (e.g. propargyl), butynyl, isoprenyl or hex-2-enyl groups. Preferably, alkenyl groups have one or two (particularly preferably one) double bonds and alkynyl groups have one or two (particularly preferably one) triple bonds.

[0041] Furthermore, the terms alkyl, alkenyl and alkynyl refer to groups in which one or more hydrogen atoms have been replaced with a halogen atom (preferably F or Cl), such as the 2,2,2-trichloroethyl or trifluoromethyl group.

[0042] The expression heteroalkyl refers to alkyl, alkenyl or alkynyl groups in which one or more (preferably 1 to 8; particularly preferably 1, 2, 3 or 4) carbon atoms are replaced by oxygen, nitrogen, phosphorus, boron, selenium, silicon or sulfur atoms (preferably oxygen, sulfur or nitrogen atoms) or by SO or SO2 groups. The expression heteroalkyl further refers to carboxylic acids or groups derived from carboxylic acids, such as acyl, acylalkyl, alkoxycarbonyl, acyloxy, acyloxyalkyl, carboxyalkylamide or alkoxycarbonyloxy. Furthermore, the term heteroalkyl refers to groups in which one or more hydrogen atoms are replaced by halogen atoms (preferably F or Cl).

[0043] Preferably, the heteroalkyl group contains 1 to 12 carbon atoms and 1 to 8 heteroatoms selected from oxygen, nitrogen and sulfur (especially oxygen and nitrogen). Particularly preferably, the heteroalkyl group contains 1 to 6 (e.g., 1, 2, 3 or 4) carbon atoms and 1, 2, 3 or 4 (especially 1, 2 or 3) heteroatoms selected from oxygen, nitrogen and sulfur (especially oxygen and nitrogen). 1~6 The term heteroalkyl refers to a heteroalkyl group containing 1 to 6 carbon atoms and 1, 2, 3 or 4 heteroatoms selected from O, S and / or N (especially O and / or N). 1~4 The term heteroalkyl refers to a heteroalkyl group containing from 1 to 4 carbon atoms and 1, 2 or 3 heteroatoms selected from O, S and / or N (especially O and / or N).

[0044] Examples of heteroalkyl groups include those of the formula: R a -OY a -, R a -SY a -, R a -SO-Y a -, R a -SO2-Y a -, R a -N(R b )-SO2-Y a -, R a -SO2-N(R b )-Y a -, R a -N(R b )-Y a -, R a -CO-Y a -, R a -O-CO-Y a -, R a -CO-OY a -, R a -CO-N(R b )-Y a -, R a -N(R b )-CO-Y a -, R a -O-CO-N(R b )-Y a -, R a -N(Rb )-CO-OY a -、-Y a -CN、R a -N(R b )-CO-N(R c )-Y a -、R a -O-WHAT-OY a -、R a -N(R b )-C(=NR d )-N(R c )-Y a -、R a -CS-Y a -、R a -O-CS-Y a -、R a -CS-OY a -、R a -CS-N(R b )-Y a -、R a -N(R b )-CS-Y a -、R a -O-CS-N(R b )-Y a -、R a -N(R b )-CS-OY a -、R a -N(R b )-CS-N(R c )-Y a -、R a -O-CS-OY a -、R a -S-WHAT-Y a -、R a -WHAT-S-Y a -、R a -S-CO-N(R b )-Y a -、R a -N(R b )-WHAT-S-Y a -、R a -S-CO-OY a -、R a -O-WHAT-S-Y a -、R a -S-WHAT-S-Y a -、R a -S-CS-Y a-, R a -CS-SY a -, R a -S-CS-N(R b )-Y a -, R a -N(R b )-CS-SY a -, R a -S-CS-OY a -, R a -O-CS-SY a - group, where R a is a hydrogen atom, C 1- C6 alkyl group, C 2- C6 alkenyl group or C 2- C6 alkynyl group; R b is a hydrogen atom, C 1- C6 alkyl group, C 2- C6 alkenyl group or C 2- C6 alkynyl group; R c is a hydrogen atom, C 1- C6 alkyl group, C 2- C6 alkenyl group or C 2- C6 alkynyl group; R d is a hydrogen atom, C 1- C6 alkyl group, C 2- C6 alkenyl group or C 2- Y is a C6 alkynyl group; a is a bond, C 1- C6 alkylene group, C 2- C6 alkenylene group or C 2- C6 alkynylene group, where each heteroalkyl group contains at least one carbon atom and one or more hydrogen atoms may be replaced by fluorine or chlorine atoms.

[0045] Illustrative examples of heteroalkyl groups are methoxy, trifluoromethoxy, ethoxy, n-propyloxy, isopropyloxy, n-butoxy, tert-butyloxy, methoxymethyl, -CHCHOH, -CHOH, -SOMe, -NHAc, -C(CH)CN, methoxyethyl, ethoxymethyl, 1-methoxyethyl, 1-ethoxyethyl, 2-methoxyethyl or 2-ethoxyethyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, diethylamino, isopropylethylamino, methylaminomethyl, ethylaminomethyl, diisopropylaminoethyl, methylthio, ethylthio, isopropylthio, enol ether, dimethylaminomethyl, dimethylaminoethyl, acetyl, propionyl, butyryloxy, acetyloxy, methoxycarbonyl, ethoxycarbonyl, propionyloxy, acetylamino or propionylamino, carboxymethyl, carboxyethyl or carboxypropyl, N-ethyl-N-methyl-carbamoyl or N-methylcarbamoyl. Further examples of heteroalkyl groups are nitrile (-CN), isonitrile, cyanate, thiocyanate, isocyanate, isothiocyanate, and alkylnitrile groups.

[0046] The term cycloalkyl refers to saturated or partially unsaturated cyclic groups (e.g. cycloalkenyl groups) containing one or more rings (preferably one or two) and containing 3 to 14 ring carbon atoms, preferably 3 to 10 (in particular 3, 4, 5, 6 or 7) ring carbon atoms. Furthermore, the term cycloalkyl refers to groups in which one or more hydrogen atoms are replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =O, SH, =S, NH2, =NH, N3 or NO2 groups, and thus cyclic ketones, such as cyclohexanone, 2-cyclohexenone or cyclopentanone. Further particular examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, spiro[4,5]decanyl, norbornyl, cyclohexyl, cyclopentenyl, cyclohexadienyl, decalinyl, bicyclo[4.3.0]nonyl, tetralin, cyclopentylcyclohexyl, fluorocyclohexyl or cyclohex-2-enyl.Preferably, the term cycloalkyl refers to saturated cyclic groups containing one or more rings (preferably one or two) and containing 3 to 14 ring carbon atoms, preferably 3 to 10 (especially 3, 4, 5, 6 or 7) ring carbon atoms.

[0047] The term heterocycloalkyl refers to a cycloalkyl group as defined above in which one or more (preferably 1, 2 or 3) ring carbon atoms are replaced by oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atoms (preferably by oxygen, sulfur or nitrogen atoms) or by a SO or SO2 group. Heterocycloalkyl groups preferably have one or two rings and 3 to 10 (in particular 3, 4, 5, 6 or 7) ring atoms, preferably selected from C, O, N and S. Furthermore, the term heterocycloalkyl refers to groups which are substituted by fluorine, chlorine, bromine or iodine atoms or by OH, =O, SH, =S, NH2, =NH, N3 or NO2 groups. Examples are piperidyl, prolinyl, imidazolidinyl, piperazinyl, morpholinyl (e.g. -N(CHCH)O), urotropinyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrofuryl or 2-pyrazolinyl groups, furthermore also lactams, lactones, cyclic imides and cyclic anhydrides.

[0048] The expression alkylcycloalkyl refers to groups which contain both a cycloalkyl group and an alkyl, alkenyl or alkynyl group as defined above, such as alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkenyl, alkenylcycloalkyl and alkynylcycloalkyl groups. Alkylcycloalkyl groups preferably contain a cycloalkyl group containing one or two rings and 3 to 10 (especially 3, 4, 5, 6 or 7) ring carbon atoms, and one or two alkyl, alkenyl or alkynyl groups (especially alkyl groups) having 1 or 2 to 6 carbon atoms.

[0049] The expression heteroalkylcycloalkyl refers to an alkylcycloalkyl group as defined above, in which one or more (preferably 1, 2 or 3) carbon atoms are replaced by oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atoms (preferably by oxygen, sulfur or nitrogen atoms) or by a SO or SO2 group. Heteroalkylcycloalkyl groups preferably contain one or two rings with 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms and one or two alkyl, alkenyl, alkynyl or heteroalkyl groups (especially alkyl or heteroalkyl groups) with 1 or 2 to 6 carbon atoms. Examples of such groups are alkylheterocycloalkyl, alkylheterocycloalkenyl, alkenylheterocycloalkyl, alkynylheterocycloalkyl, heteroalkylcycloalkyl, heteroalkylheterocycloalkyl and heteroalkylheterocycloalkenyl, the cyclic groups being saturated or mono-, di- or tri-unsaturated.

[0050] The term aryl refers to aromatic groups containing one or more rings and 6 to 14 ring carbon atoms, preferably 6 to 10 (especially 6) ring carbon atoms. Furthermore, the term aryl refers to groups substituted by fluorine, chlorine, bromine or iodine atoms or by OH, SH, NH2, N3 or NO2 groups. Examples are phenyl (Ph), naphthyl, biphenyl, 2-fluorophenyl, anilinyl, 3-nitrophenyl or 4-hydroxyphenyl groups.

[0051] The term heteroaryl refers to an aromatic group containing one or more rings and 5 to 14 ring atoms, preferably 5 to 10 (in particular 5 or 6 or 9 or 10) ring atoms, including one or more (preferably 1, 2, 3 or 4) oxygen, nitrogen, phosphorus or sulfur ring atoms (preferably O, S or N). Furthermore, the term heteroaryl refers to groups substituted by fluorine, chlorine, bromine or iodine atoms or by OH, SH, N3, NH2 or NO2 groups. Examples include pyridyl groups (e.g., 4-pyridyl groups), imidazolyl groups (e.g., 2-imidazolyl groups), phenylpyrrolyl groups (e.g., 3-phenylpyrrolyl groups), thiazolyl groups, isothiazolyl groups, 1,2,3-triazolyl groups, 1,2,4-triazolyl groups, oxadiazolyl groups, thiadiazolyl groups, indolyl groups, indazolyl groups, tetrazolyl groups, pyrazinyl groups, pyrimidinyl groups, pyridazinyl groups, 4-hydroxypyridyl groups (4-pyridonyl groups), 3,4-hydroxypyridyl groups ( 3,4-pyridonyl group), oxazolyl group, isoxazolyl group, triazolyl group, tetrazolyl group, isoxazolyl group, indazolyl group, indolyl group, benzimidazolyl group, benzoxazolyl group, benzisoxazolyl group, benzthiazolyl group, pyridazinyl group, quinolinyl group, isoquinolinyl group, pyrrolyl group, purinyl group, carbazolyl group, acridinyl group, pyrimidyl group, 2,3'-bifuryl group, pyrazolyl group (e.g., 3-pyrazolyl group), and isoquinolinyl group.

[0052] The term aralkyl refers to groups containing both an aryl group according to the above definition and an alkyl, alkenyl, alkynyl and / or cycloalkyl group, such as arylalkyl, arylalkenyl, arylalkynyl, arylcycloalkyl, arylcycloalkenyl, alkylarylcycloalkyl and alkylarylcycloalkenyl groups. Specific examples of aralkyl are phenylcyclopentyl, cyclohexylphenyl and groups derived from toluene, xylene, mesitylene, styrene, benzyl chloride, o-fluorotoluene, 1H-indene, tetralin, dihydronaphthalene, indanone, cumene, fluorene and indane. The aralkyl group preferably comprises one or two aromatic ring systems (especially one or two rings) each containing 6 to 10 carbon atoms and one or two alkyl, alkenyl and / or alkynyl groups containing 1 or 2 to 6 carbon atoms and / or one or two cycloalkyl groups containing 3, 4, 5, 6 or 7 ring carbon atoms.

[0053] The term heteroaralkyl refers to groups that contain both aryl and / or heteroaryl groups as defined above, and alkyl, alkenyl, alkynyl and / or heteroalkyl groups and / or cycloalkyl and / or heterocycloalkyl groups. Heteroaralkyl groups preferably contain one or two aromatic ring systems (especially one or two rings) each containing 5 or 6 to 9 or 10 ring atoms (preferably selected from C, N, O and S) and one or two alkyl, alkenyl and / or alkynyl groups containing 1 or 2 to 6 carbon atoms and / or one or two heteroalkyl groups containing 1 to 6 carbon atoms and 1, 2 or 3 heteroatoms selected from O, S and N and / or one or two cycloalkyl groups each containing 3, 4, 5, 6 or 7 ring carbon atoms and / or one or two heterocycloalkyl groups each containing 3, 4, 5, 6 or 7 ring atoms including 1, 2, 3 or 4 oxygen, sulphur or nitrogen atoms.

[0054] Examples are arylheteroalkyl groups, arylheterocycloalkyl groups, arylheterocycloalkenyl groups, arylalkylheterocycloalkyl groups, arylalkenylheterocycloalkyl groups, arylalkynylheterocycloalkyl groups, arylalkylheterocycloalkenyl groups, heteroarylalkyl groups, heteroarylalkenyl groups, heteroarylalkynyl groups, heteroarylheteroalkyl groups, heteroarylcycloalkyl groups, heteroarylcycloalkenyl groups, heteroarylheterocycloalkyl groups, heteroarylheterocycloalkenyl groups, heteroarylalkylcycloalkyl groups, heteroarylalkylheterocycloalkenyl groups, heteroarylheteroalkylcycloalkyl groups, heteroarylheteroalkyl-cycloalkenyl groups and heteroarylheteroalkylheterocycloalkyl groups, where the cyclic groups are saturated or mono-, di- or tri-unsaturated. Specific examples are tetrahydroisoquinolinyl groups, benzoyl groups, phthalidyl groups, 2- or 3-ethylindolyl groups, 4-methylpyridino groups, 2-, 3- or 4-methoxyphenyl groups, 4-ethoxyphenyl groups, 2-, 3- or 4-carboxyphenylalkyl groups.

[0055] As already mentioned above, the expressions cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl also refer to groups which are substituted by fluorine, chlorine, bromine or iodine atoms or by OH, ═O, SH, ═S, NH, ═NH, N or NO groups.

[0056] According to preferred embodiments, all alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl groups described herein may be optionally substituted.

[0057] The term halogen refers to F, Cl, Br or I.

[0058] When an aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, or heteroaralkyl group contains multiple rings, the rings can be joined to each other through single or double bonds, or the rings can be cyclized, fused, or bridged.

[0059] For example, the suffix "-ene," as in "phenylene," refers to the corresponding divalent radical.

[0060] The term "optionally substituted" refers to a group that is unsubstituted or substituted with one or more (especially 1, 2 or 3, preferably 1 or 2) substituents. When a group contains multiple substituents, the substituents are independently selected, i.e., they can be the same or different.

[0061] When a group is substituted with a cyclic group, such as a cycloalkyl group or a heterocycloalkyl group, the cyclic group may be attached to the group through a single or double bond, or the cyclic group may be cyclized or fused to the group.

[0062] Specific examples of substituents are fluorine, chlorine, bromine and iodine, as well as OH, SH, NH, -SOH, -SONH, -COOH, -COOMe, -COMe(Ac), -NHSOMe, -SONMe, -CHNH, -NHAc, -SOMe, -CONH, -CN, -NHCONH, -NHC(NH)NH, -NOHCH, -N, and -NO.

[0063] Further examples of substituents include C1-C 10 Alkyl groups, C2-C 10 Alkenyl groups, C2-C10 Alkynyl groups, C1-C 10 Heteroalkyl groups, C3-C 18 Cycloalkyl groups, C1-C 17 Heterocycloalkyl groups, C4-C 20 Alkylcycloalkyl groups, C1-C 19 Heteroalkylcycloalkyl groups, C6-C 18 Aryl groups, C1-C 17 Heteroaryl groups, C7-C 20 Aralkyl groups and C1-C 19 Heteroaralkyl groups; in particular, C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C1-C6 heteroalkyl groups, C3-C 10 Cycloalkyl groups, C1-C9 heterocycloalkyl groups, C4-C 12 Alkylcycloalkyl groups, C1-C 11 Heteroalkylcycloalkyl groups, C6-C 10 Aryl groups, C1-C9 heteroaryl groups, C7-C 12 Aralkyl groups and C1-C 11 Heteroaralkyl groups, more preferably C1-C6 alkyl groups and C1-C6 heteroalkyl groups.

[0064] Preferred substituents are halogen atoms (e.g., F, Cl, Br) and -OH groups, -NH2 groups, -CN groups, C1-C6 alkyl groups, C2-C6 alkenyl groups, C1-C6 heteroalkyl groups, cyclopropyl groups and -CH2-cyclopropyl groups.

[0065] Further preferred substituents are halogen atoms (e.g., F, Cl, Br), as well as OH groups, -NH groups, -CN groups, -C 1~4 Alkyl groups (e.g., -Me, -Et, -nPr, -iPr, -nBu, -iBu, -tBu, -CH2CH2F, CH2CHF2, -CH2CF3, and -CF3), -OC 1~4 Alkyl groups (e.g., -OMe, -OEt, -O-nPr, -O-iPr, -O-nBu, -O-iBu and -O-tBu), -NHC 1~6Alkyl groups (e.g., -NH(CH2)2F and -NH(CH2)3F), -NH(CH2)2OH, -NH(CH2)3OH, -NH(CH2)2OMe, -NH(CH2)3OMe, -N(Me)(CH2)2OH, -N(Me)(CH2)3OH, -N(Me)(CH2)2OMe, -N(Me)(CH2)3OMe, -N(C 1~6 alkyl)2, -C(CH3)2CN, -CONH-C 1~4 Alkyl (e.g. -CONHCH2CF3, -CONHEt, -CONH t Bu), -COOH, -COOMe, -COMe, -CH2CH2CH=CH2, a cyclopropyl group, and a -CH2-cyclopropyl group.

[0066] Therapeutic uses, as well as formulations and pharmaceutical compositions, of the compounds of formula (I), their pharmacologically acceptable salts, solvates and hydrates, respectively, are also within the scope of the present invention.

[0067] The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) as defined herein or a salt thereof, or a pharma- ceutically acceptable ester, prodrug, hydrate or solvate thereof, optionally in combination with a pharma- ceutically acceptable carrier and / or adjuvant.

[0068] It is a further object of the present invention to provide a compound of formula (I) as defined herein or a pharmaceutical composition as defined herein for the preparation of a medicament for the treatment of one or more of the diseases identified herein.

[0069] Preferably, the compounds of the invention can be used in the treatment and / or prevention of the following conditions: Diseases in which aberrant CDK (particularly CDK9 and / or CDK2) regulation is observed, such as a wide range of cytokine-induced inflammatory and autoimmune diseases, local or systemic viral infections, viral infections of the eye, viral respiratory infections, or viral infections of the central and / or peripheral nervous system caused by DNA and / or RNA viruses, as well as various non-solid and solid malignancies, cancers, or hyperproliferative diseases, such as acute myeloid leukemia, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute biphenotypic leukemia, aggressive MYC-driven B-Cell lymphoma, primary peritoneal carcin ... carcinoma), Kaposi's sarcoma, advanced breast cancer, non-small cell lung cancer, colorectal cancer, or liver cancer such as hepatocellular carcinoma, cervical intraepithelial neoplasia, prostate cancer, melanoma, glioma, glioblastoma, neuroblastoma, astrocytoma, anaplastic astrocytoma, or glioblastoma, advanced and / or metastatic hematological / solid malignancies, for example. In particular, the compounds can be used to treat hematological malignancies or solid tumors caused by aberrant expression of MYC- or MCL-1. Furthermore, the compounds can be used as modulators of the immune response and can be used for the treatment and / or prevention of mechanical / trauma-induced inflammation, such as post-traumatic osteoarthritis (PTOA), systemic and local cytokine-induced inflammatory diseases, such as inflammatory diseases of the gastrointestinal or urinary tract, and inflammatory diseases of the eye, such as Sjogren's disease and glaucoma, bacterial-induced inflammatory diseases, such as gingivitis, periodontitis, and for the treatment and / or prevention of cardiovascular diseases, such as cardiac hypertrophy, dilated cardiomyopathy, atherosclerosis, and cardiometabolic diseases, such as obesity and diabetes.

[0070] A therapeutically effective amount of a compound according to this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is within the skill of one in the art.

[0071] The therapeutically effective amount or dosage of the compounds according to the invention can vary within wide limits and can be determined in a manner known in the art. Such dosage can be adjusted to the individual requirements in each particular case, including the specific compound administered, the route of administration, the condition being treated, and the patient being treated.

[0072] The salt of the compound of formula (I) is preferably a pharmacologically acceptable salt.The examples of the pharmacologically acceptable salt of the sufficiently basic compound of formula (I) are the salts of physiologically acceptable mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid; or the salts of organic acids such as methanesulfonic acid, p-toluenesulfonic acid, lactic acid, acetic acid, trifluoroacetic acid, citric acid, succinic acid, fumaric acid, maleic acid and salicylic acid.Furthermore, the sufficiently acidic compound of formula (I) can form alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts, lithium salts, calcium salts or magnesium salts; ammonium salts; or organic base salts, such as methylamine salts, dimethylamine salts, trimethylamine salts, triethylamine salts, ethylenediamine salts, ethanolamine salts, choline hydroxide salts, meglumine salts, piperidine salts, morpholine salts, tris-(2-hydroxyethyl)amine salts, lysine salts or arginine salts; all of these are also further examples of the salt of formula (I).

[0073] The compounds of formula (I) may be solvated, in particular hydrated. Hydration / hydration may occur during the preparation process or as a result of the hygroscopic nature of the compounds of formula (I) that do not initially contain water. Solvates and / or hydrates may exist, for example, in solid or liquid form.

[0074] It should be understood that certain compounds of formula (I) may have tautomers, of which only one may be specifically mentioned or depicted in the following description, different geometric isomers (usually designated as cis / trans isomers or more commonly as (E) and (Z) isomers), or different optical isomers (usually named according to the Cahn-Ingold-Prelog or R / S system) resulting from one or more chiral carbon atoms. All these tautomers, geometric or optical isomers (as well as racemates and diastereomers) and polymorphs are included in the present invention. Compounds of formula (I) may contain asymmetric C atoms and therefore may exist either as achiral compounds, mixtures of diastereomers, mixtures of enantiomers or optically pure compounds. The present invention includes both all pure enantiomers and all pure diastereomers, as well as mixtures thereof in any mixture ratio.

[0075] According to a further embodiment of the present invention, one or more hydrogen atoms of the compounds of the present invention can be replaced with deuterium. Deuterium modification improves the metabolic properties of a drug with little or no change in its inherent pharmacology. Deuterium substitution at specific molecular positions improves metabolic stability, reduces the formation of toxic metabolites, and / or increases the formation of desired active metabolites. Thus, the present invention also encompasses partially and fully deuterated compounds of formula (I). The term hydrogen also encompasses deuterium.

[0076] The present invention also relates to prodrugs consisting of a compound of formula (I) and at least one pharmacologically acceptable protecting group that is cleaved under physiological conditions, examples of which include alkoxy-, arylalkyloxy-, acyl-, acyloxymethyl groups (e.g., pivaloyloxymethyl), 2-alkyl-, 2-aryl- or 2-arylalkyl-oxycarbonyl-2-alkylideneethyl groups, or acyloxy groups as defined herein, such as ethoxy, benzyloxy, acetyl or acetyloxy, or, in particular, in the case of compounds of formula (I) with a hydroxy group (-OH), sulfate, phosphate (-OPO3 or OCH2OPO3) or esters of amino acids. Particularly preferred are prodrugs of the hydroxy group of compounds of formula (I).

[0077] As used herein, the term pharma- ceutically acceptable ester refers specifically to esters that hydrolyze in vivo, including esters that decompose easily in the human body to leave the parent compound or its salt.Suitable ester groups include, for example, those derived from pharma-ceutically acceptable aliphatic carboxylic acids, particularly alkanoic acid, alkenoic acid, cycloalkanoic acid and alkanedioic acid, each alkyl or alkenyl moiety advantageously having 6 or less carbon atoms.Specific examples of esters include, but are not limited to, formate, acetate, propionate, butyrate, acrylate and succinate ethyl ester.

[0078] Preferably, the present invention also relates to prodrugs, biohydrolyzable esters, biohydrolyzable amides, polymorphs, tautomers, stereoisomers, metabolites, N-oxides, biohydrolyzable carbamates, biohydrolyzable ethers, physiologically functional derivatives, atropisomers, or in vivo hydrolyzable precursors, diastereomers or mixtures of diastereomers, chemically protected forms, affinity reagents, complexes, chelates and stereoisomers of the compounds of formula (I).

[0079] As mentioned above, therapeutically useful agents containing the compounds of formula (I), their solvates, salts or formulations are also included within the scope of the present invention. In general, the compounds of formula (I), alone or in combination with any other therapeutic agent, are administered by using known and acceptable modes known in the art.

[0080] For oral administration, such therapeutically useful agents may be administered by one of the following routes: orally, for example, in the form of tablets, dragees, coated tablets, pills, semisolids, soft or hard capsules, such as soft and hard gelatin capsules, aqueous or oily solutions, emulsions, suspensions or syrups, parenterally, for example, by intravenous, intramuscular and subcutaneous injection, for example as injectable solutions or suspensions, rectally as suppositories, by inhalation or insufflation, for example as powder formulations, microcrystals or sprays (for example liquid aerosols), transdermally, for example via transdermal delivery systems (TDS), such as plasters containing the active ingredient, or intranasally. For the preparation of such tablets, pills, semisolids, coated tablets, sugar-coated tablets, and hard capsules, such as gelatin capsules, the therapeutically useful products can be mixed with pharma- ceutically inert inorganic or organic excipients, such as lactose, sucrose, glucose, gelatin, malt, silica gel, starch or its derivatives, talc, stearic acid or its salts, skimmed milk powder, etc. For the preparation of soft capsules, excipients such as vegetable oils, petroleum, animal oils or synthetic oils, waxes, fats, polyols, etc. can be used. For the preparation of solutions, emulsions or suspensions or syrups, excipients such as water, alcohol, saline, aqueous glucose solution, polyols, glycerin, lipids, phospholipids, cyclodextrins, vegetable oils, petroleum, animal oils or synthetic oils can be used. Particularly preferred are lipids, more preferably phospholipids (preferably of natural origin, particularly preferably with a particle size between 300 and 350 nm) that are preferred in phosphate-buffered saline (pH=7-8, preferably 7.4). In the case of suppositories, excipients can be, for example, vegetable oils, petroleum oils, animal oils or synthetic oils, waxes, fats and polyols.In the case of aerosol preparations, compressed gases suitable for this purpose can be used, for example, oxygen, nitrogen and carbon dioxide.The pharma-ceutically useful agent can also contain additives for preservation and stabilization, for example, UV stabilizers, emulsifiers, sweeteners, flavorings, salts for changing osmotic pressure, buffers, coating additives and antioxidants.

[0081] In general, when administered orally or parenterally to an adult weighing approximately 80 kg, the daily dose is about 0.1 mg to about 10,000 mg, preferably about 1 mg to about 1,000 mg, but may exceed the upper limit if necessary. The daily dose may be administered in a single dose or divided doses, and when administered parenterally, it may be given as continuous infusion or subcutaneous injection.

[0082] According to a further preferred embodiment, the present invention provides a method for treating one or more of the diseases identified herein, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof.

[0083] According to a further preferred embodiment, the present invention provides a method for treating one or more of the diseases identified herein, comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof. EXAMPLES

[0084] General synthesis method The following methods were used in the synthesis of the compounds described herein. Flash Chromatography: Flash chromatography was performed on a Biotage Isolera® or Selekt® system using SNAP or SFAR silica cartridges and gradients of ethyl acetate / cyclohexane / methanol or dichloromethane / methanol as eluents. Microwave conditions: Reactions under microwave conditions are carried out in a Biotage initiator® microwave system.

[0085] Semi-preparative reversed-phase chromatography: For semi-preparative reversed-phase chromatography, the following equipment was used: 2x Varian PrepStar SD-1, 1x Dionex P580 pump 1 channel (MakeUP I), 1x Dionex AXP-MS (MakeUP II), 1x Dionex MSQ, 1x Dionex UVD 340V-preparative flow cell, Gilson215 liquid handler, SunFire Prep C18 OBD 5μm, 19x50mm column, 1x G7159B 1290 Infinity II preparative open-bed sampler / collector, 1x G7161B 1290 Infinity II preparative binary pump, 1x G7111B 1260 Infinity II quaternary pump (modifier), 1x G7111B 1260 Infinity II quaternary pump (analytical / makeup), 1x G7165A 1260 Infinity II 1x G7170B 1290 Infinity II MS Flow Modulator including Multi-Wavelength Detector, Flow Cell (product no. G1315-60022, serial no. DE185H6157, path length 10.00 mm, volume 13.00 μl), 1x G6125B MSD 6100 Series Single Quadrupole including G1948B Electrospray Interface, and 3x G1170A 1290 Infinity Valve Drives (14-port, 6-position valve head for analytical column selection; 14-port, 6-position valve head for preparative column selection; 14-port, 2-position valve head for analytical / preparative mode selection). Preparative columns: Waters SunFire preparative C18 5μm OBD 30x100mm, #186002572, Waters AtlantisT3 preparative 5μm OBD 30x100mm, #186003702, and Waters XSelect CSH preparative C18 5μm OBD 30x100mm, #186005425. Analytical columns: Waters SunFire C18 2.5μm 3.0x75mm, #186005636, Waters Atlantis T3 3μm 3.0x75mm, #186005653, and Waters XSelect CSH C18 2.5μm 3.0x75mm, #186006106.

[0086] Typical chromatographic conditions are as follows: The column flow rate was 30 mL / min, solvent A was methanol containing 0.3% acetic acid, and solvent B was water containing 0.3% acetic acid. Typical times and relative amounts of Solvent B and Solvent B are shown in Table 1.

[0087] [Table 1]

[0088] Typical preparative method: column flow rate was 60 mL / min, solvent A was acetonitrile and solvent B was water. Preparations included modifier flows: 1.8 mL / min modifier flow rate containing 10% acetic acid in acetonitrile / water 1:1 => acetic acid in the flow rate is 0.3%; 0.5 M NH4Ac / NH4OH buffer (pH 9.2) in acetonitrile / water 1:9 => buffer concentration in the flow rate is 15 mM. MS make-up: 0.05% acetic acid in acetonitrile / water 1:1 at 0.9 mL / min. For example, a typical focusing gradient timetable for the 59.7% elution point is shown in Table 2.

[0089] [Table 2]

[0090] Typical analytical modifiers: column flow rate 1 mL / min, solvent A was acetonitrile, solvent B was water, and solvent C was 5% acetic acid in acetonitrile / water 1:1. Typical times and relative amounts of Solvent A, Solvent B, and Solvent C are shown in Table 3.

[0091] [Table 3]

[0092] For detection, a mass spectrometer detector (API-ES, positive) with UV 220 nm, 254 nm or 310 nm was used.

[0093] The terms and abbreviations used in the examples are shown in Table 4.

[0094] [Table 4]

[0095] The analytical HPLC methods used in the preparation of the compounds are shown in Table 5.

[0096] [Table 5]

[0097] A general route to pyrazolotriazines. :

[0098] [ka]

[0099] Description of synthesis steps : Amide Coupling :

[0100] [ka]

[0101] Starting from the acid chloride: The aminopyrazole was dissolved in CH2Cl2, cooled to 0 °C, and DIPEA (3 equiv.) and the corresponding acid chloride (2.5 equiv.) were added. The mixture was stirred at room temperature for 2 h. The reaction was diluted with aqueous NaHCO3, extracted with CH2Cl2, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was dissolved in THF / MeOH and treated with 2M NaOH (2 equiv.) overnight. The pH was adjusted to 8 with 1M HCl, and the mixture was extracted with DCM. The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure. The product was used without further purification.

[0102] cyclization

[0103] [ka]

[0104] The amide was dissolved in DCM followed by the addition of methyl thiocyanate (2 eq.) and 2-chloropyridine (1.2 eq.). The reaction mixture was flushed with N2 for a few minutes and then cooled to -78°C. Tf2O (2 eq.) was added slowly. The reaction mixture was stirred at -78°C for 40 minutes and then at 0°C for 20 minutes. Finally, the reaction mixture was microwaved at 140°C for 20 minutes. The reaction mixture was diluted with DCM and washed with water, NaHCO3 twice, 2M HCl twice, and water again. The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography.

[0105] replacement [ka]

[0106] Method A : The amine was dissolved in dry EtOH. Then the triazine and DIPEA 20% (v / v) were added. The reaction mixture was flushed with N2 and heated under microwave conditions at 140° C. for 30 min. The mixture was concentrated and purified by reverse phase HPLC. Method B : The amine was dissolved in dry EtOH. Then the triazine and a few drops of 4M HCl in dioxane were added. The reaction mixture was flushed with N2 and heated at 140° C. under microwave conditions for 60 min. The mixture was concentrated and purified by reverse phase HPLC.

[0107] The following compounds were synthesized using these protocols: Synthesized by Method A: Examples #68, #69, #75, #88, #90, #92, #94, #106, #107, #108, #109, #110, #111, #112, #113, #115, #116, #117, #118, #119, #120, #124, #125, #126, #127, #128, #129, #130, #131, #132, #133, #134, #135, #138, #141, #142, #143, #144, #145, #146 Synthesized by Method B: Examples: #8, #12, #13, #14, #15, #16, #17, #18, #19, #20, #21, #22, #23, #24, #25, #26, #27, #28, #29, #30, #31, #32, #33, #34, #35, #36, #37, #38, #39, #40, #41, #42, #43, #44, #45, #46, #47, #48, #49, #50, #51, #52, #53, # 54, #55, #56, #57, #58, #59, #60, #61, #62, #64, #65, #66, #67, #70, #71, #72, #73, #74, #76, #77, #78, #79, #80, #81, #82, #83, #84, #85, #86, #87, #89, #91, #93, #95, #96, #97, #98, #99, #100, #101, #102, #103, #104, #105, #114

[0108] Special cases: Example #140: The compound of Example #70 was dissolved in DCM, followed by the addition of NIS (2 eq.). After 5 h, additional NIS (2 eq.) was added. The mixture was stirred at room temperature overnight. The mixture was quenched with sodium thiosulfate (5% aqueous solution), extracted with DCM, dried (Na2SO4), filtered, and concentrated under reduced pressure. A small sample was purified by reverse phase HPLC, and the remainder was used without further purification.

[0109] Example #139: The product of Example #140 was dissolved in DMF. Ethynyltrimethylsilane (1.1 eq), CuI (0.1 eq), Pd(PPh3)2Cl2 (0.05 eq) and diisopropylamine (50% v / v) were added. The mixture was heated at 120° C. for 1 h under microwave conditions. The mixture was filtered through a syringe filter and purified by flash gradient chromatography. The product was dissolved in DCM and treated with K2CO3 (2 eq) for 1 h. The mixture was filtered, concentrated under reduced pressure and purified by reverse phase HPLC.

[0110] The amines used were either commercially available, described in the literature, or made by one of the following procedures.

[0111] A: Aryl piperazine / aryl morpholine

[0112] [ka]

[0113] Step 1 Fluoronitroalkoxybenzene and amine (5 equiv.) were mixed in dry MeCN. The mixture was heated at 160° C. for 20 min under microwave irradiation. The mixture was concentrated, redissolved in EtOAc and washed with water. The organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was triturated with diethyl ether. Step 2: The product from step 1 was dissolved in EtOH and Pd / C (5 mol%, 10% Pd on charcoal) was added. The atmosphere was changed to H2 and the mixture was stirred at room temperature. The mixture was filtered through Celite, washed with MeOH and concentrated under reduced pressure.

[0114] The following intermediates were synthesized according to this general procedure:

[0115] [ka]

[0116] B: Arylpiperidines / Tetrahydropyridines

[0117] [ka]

[0118] Step 1 The aryl bromide, CsCO3 (3 equiv.), Pd(dppf) (0.6 equiv.) and borolane (1.2 equiv.) were dissolved in DFM and the mixture was degassed and heated at 80° C. for 24 h. The mixture was diluted with water, neutralized with 1M HCl and extracted with DCM. The organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography. Step 2 : The product of the previous step was dissolved in DCM and HCl in dioxane (4M, 50% v / v) was added. The mixture was stirred at room temperature overnight. The mixture was diluted with water, neutralized with NaOH (6M) and extracted with DCM. The organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was used without further purification. Step 3: The product from the previous step, the corresponding aldehyde source (paraformaldehyde or (1-ethoxycyclopropoxy)trimethylsilane, 10 equiv.), acetic acid (15 equiv.) and sodium cyanoborohydride (12 equiv.) were mixed in MeOH. The mixture was stirred at 60° C. for 2 h. The mixture was concentrated, redissolved in EtOAc, washed with NaHCO3 (sat. aq.), dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography.

[0119] Step 4 : The product of step 3 was dissolved in EtOH / water (5 / 1) and iron (10 equiv.), ammonium chloride (10 equiv.) and a few drops of HCL (2M aq.) were added. The mixture was heated at 50° C. for 2 h. The mixture was filtered through Celite, washed with MeOH and DCM, concentrated, redissolved in EtOAc and basified with aqueous NaOH. The aqueous layer was extracted (EtOAc) and the organic layer was washed with water, dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography. Step 5 : The product of step 3 was dissolved in MeOH, Pd (0.1 eq., 10% on charcoal) was added and the mixture was stirred under hydrogen atmosphere overnight. The mixture was filtered through Celite, washed with MeOH and concentrated under reduced pressure. The product was used without further purification.

[0120] The following intermediates were synthesized according to this procedure:

[0121] [ka]

[0122] C: 1-(1-(tert-butyl)piperidin-4-yl)-3-methoxy-1H-pyrazol-4-amine:

[0123] [ka]

[0124] Step 1: Nitromethoxypyrazole was dissolved in THF. Piperidine alcohol (1 eq) and triphenylphosphine (1.1 eq) were added and the mixture was cooled to 0° C. DIAD (1.2 eq) was added and the mixture was allowed to warm to room temperature overnight. The mixture was concentrated and purified by gradient flash chromatography. The crude product was dissolved in EtOAc and washed successively with aqueous NaOH, aqueous HCl and aqueous NaOH. The organic layer was dried (Na2SO4), filtered and the solvent was evaporated. Step 2 : The product from step 1 was dissolved in EtOH / water (5 / 1). Iron (10 equiv.), ammonium chloride (10 equiv.), and a few drops of aqueous HCL were added. The mixture was heated at 50° C. for 1 h, filtered through Celite, and washed with MeOH and DCM. The filtrate was concentrated, basified, redissolved in EtOAc, and washed with water. The organic layer was dried (Na2SO4), filtered, and the solvent was evaporated. The product was used without further purification.

[0125] D: 1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-amine / 1-(1'-methyl-[1,4'-bipiperidine]-4-yl)-1H-pyrazol-4-amine :

[0126] [ka]

[0127] Step 1 : Piperidine nitropyrazole was dissolved in MeOH and cooled to 0°C. Ketone (2 eq), AcOH (5 eq) and NaCNBH3 (5 eq) were added. The mixture was heated to reflux overnight. The mixture was diluted with DCM and basified with NaOH (6M aq.). The layers were separated and the organic layer was washed with water and brine. The organic layer was dried (Na2SO4), filtered and the solvent was evaporated. The crude product was purified by gradient flash chromatography. Step 2 The reduction was carried out using the method in step 2 of :C.

[0128] The following intermediates were synthesized using these methods:

[0129] [ka]

[0130] E: Chloro-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-amine : E1: 5-chloro-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-amine :

[0131] [ka]

[0132] Step 1 4-(5-chloro-4-nitro-1H-pyrazol-1-yl)-1-(tetrahydro-2H-pyran-4-yl)piperidine (from step 1 of D) was dissolved in THF followed by the addition of hexachloroethane (1.3 equiv.). The mixture was cooled to -78°C and LiHMDS (1M in THF) was added dropwise. The mixture was stirred at -78°C for 2 hours. The cooling was removed and ammonium chloride (sat. aq.) was added. The mixture was diluted with water and extracted with EtOAc. The organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography. Step 2 The reduction was carried out using the method in step 2 of :C.

[0133] E2: 3-chloro-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-amine

[0134] [ka]

[0135] Step 1 : The nitrochloropyrazole was dissolved in DMF and the mesylate (1.1 equiv.) and CsCO3 (1.8 equiv.) were added. The mixture was heated at 100°C overnight. The mixture was diluted with EtOAc, washed with water and brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography. Step 2: The product from step 1 was dissolved in MeOH and treated with HCl in dioxane (4M) for 30 min at room temperature. The mixture was concentrated under reduced pressure and used as the HCl salt without further purification.

[0136] Step 3 : The product from step 2 was dissolved in DCM and HOAc (1.2 eq) and ketone (1 eq) were added. The mixture was cooled to 0° C. followed by the addition of triacetoxyborohydride (2 eq). The mixture was allowed to warm to room temperature and stirred for 8 h. Additional ketone (0.5 eq), HOAc (1.2 eq) and triacetoxyborohydride (2 eq) were added. The mixture was stirred for 2 days. The mixture was diluted with DCM and basified with NaOH (6M). The mixture was extracted several times with DCM and the organic layer was washed with water and brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography. Step 4 The reduction was carried out using the method in step 2 of :C.

[0137] F: 1-(trans)-4-morpholinocyclohexyl)-1H-pyrazol-4-amine :

[0138] [ka]

[0139] Step 1 : The nitropyrazole was dissolved in DMF and the mesylate (1.3 eq.) and CsCO3 (1.5 eq.) were added. The mixture was stirred at 100° C. overnight. The mixture was poured into water and stirred for 1 h. The crude product was collected by filtration, washed with water, and purified by recrystallization from MeOH. Step 2 : The product from step 1 was dissolved in MeOH and treated with HCL 4M in dioxane at room temperature for 30 min. The mixture was concentrated under reduced pressure, redissolved in water, basified to pH 12 with aqueous NaOH, and extracted with EtOAc. The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure. The product was used as the free base without further purification.

[0140] Step 3 : The product from step 2 was dissolved in DMF. 1-Bromo-2-(2-bromoethoxy)ethane (5 eq.) and DIPEA (5 eq.) were added and the mixture was stirred at 120° C. overnight. The mixture was diluted with water and extracted with EtOAc, and the organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography. Step 4 The reduction was carried out using the method in step 2 of :C.

[0141] G: 1-(1-(cyclopropylmethyl)piperidin-4-yl)-1H-pyrazol-4-amine :

[0142] [ka]

[0143] Step 1 : The piperidine nitropyrazole was dissolved in dichloroethane, the aldehyde (1.2 eq.) and sodium triacetoxyborohydride (1.5 eq.) were added, and the mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with NaHCO3 (sat. aq.), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by gradient flash chromatography. Step 2 : The product from step 1 was dissolved in MeOH and Pd (0.1 eq.; 5% on charcoal) was added. The mixture was stirred overnight under hydrogen atmosphere. The mixture was filtered through Celite, washed with MeOH and concentrated under reduced pressure. The product was used without further purification.

[0144] H: 4-(piperidin-1-yl)cyclohexanamine :

[0145] [ka]

[0146] Step 1The boc-protected diamine was dissolved in acetonitrile. Dibromopentane (2 eq.) and DIPEA (5 eq.) were added and the mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with ammonium chloride (sat. aq.) and water. The organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by reverse phase HPLC. Step 2 : The product from step 1 was dissolved in MeOH and treated with HCl (4M in dioxane, excess) overnight. The mixture was concentrated and used as the HCl salt without further purification.

[0147] The following intermediates were synthesized according to these protocols:

[0148] [ka]

[0149] I: Alkylcyclohexaneamine : I1: Primary alkylcyclohexanamine :

[0150] [ka]

[0151] Step 1 The boc-protected cyclohexanediamine was dissolved in acetonitrile and an alkyl bromide (1 eq.) and K2CO3 (2.5 eq.) were added. The mixture was heated at 80° C. overnight. The mixture was filtered through Celite, concentrated under reduced pressure, and used without further purification. Step 2 : The mixture from step 1 was dissolved in DCM / TFA (2 / 1), stirred at room temperature for 1 h, and concentrated under reduced pressure. The product was used without further purification.

[0152] The following intermediates were synthesized using these methods:

[0153] [ka]

[0154] I2: Secondary alkylcyclohexaneamine : [ka]

[0155] Step 1 The corresponding product from step 1 of I2 was taken up in MeOH, paraformaldehyde (5 eq.), AcOH (5 eq.) and sodium cyanoborohydride (5 eq.) were added and the mixture was stirred at room temperature overnight. The mixture was basified with aqueous NaOH, extracted with EtOAc, washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was used without further purification. Step 2 : The product of step 1 was deprotected using the method of step 2 of I1.

[0156] The following intermediates were synthesized using these methods:

[0157] [ka]

[0158] The following examples were prepared according to the procedures above. Example No.: Name; HPLC-MS-Method; Retention time (min); m+H Observed; NMR

[0159] Example 8 2-(2,6-difluorophenyl)-N-(3-ethoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS B; 2.656; 466.25;

[0160] Example #12:2-(2,6-dichlorophenyl)-N-(3-ethoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 3.683; 498.2; 1H NMR (400 MHz, MeOD) δ = 8.24 (d, J = 2.1 Hz, 1H), 7.64 - 7.57 (m, 1H), 7.52 (dd, J = 8.0, 1.2 Hz, 2H), 7.45 (dd, J = 9.2, 6.8 Hz, 1H), 7.34 - 7.21 (m, 1H), 6.99 (d, J = 8.6 Hz, 1H), 6.59 (d, J = 2.1 Hz, 1H), 4.07 (q, J = 6.9 Hz, 2H), 3.32 - 3.23 (m,4H), 3.17 - 3.11 (m, 2H), 2.79 (s, 3H), 2.48 (s, 3H), 1.38 (t, J = 7.0 Hz, 3H)

[0161] Example #13:2-(2,6-dichlorophenyl)-N-(3-ethoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 3.958; 495.2; 1H NMR (400 MHz, CDCl3) δ = 12.23 - 12.16 (m, 1H), 11.60 (t, J = 2.3 Hz, 1H), 11.51 - 11.43 (m, 2H), 11.43 - 11.36 (m, 1H), 11.22 (dt, J = 8.2, 2.3 Hz, 1H), 11.12 (dd, J = 8.2, 4.4 Hz, 1H), 10.55 (dd, J = 4.6, 2.1 Hz, 1H), 9.75 (d, J = 3.9 Hz, 1H), 8.82 (d, J = 4.0 Hz, 29H), 8.02 - 7.91 (m, 2H), 7.40 (q, J = 3.7, 3.1 Hz, 2H), 7.27 (dp, J = 3.2, 1.7 Hz, 6H), 6.97 (t, J = 5.6 Hz, 2H), 6.68 (s, 2H), 6.59 (d, J = 4.3 Hz, 2H), 5.88 (d, J = 4.3 Hz, 2H), 5.26 (td, J = 6.9, 4.4 Hz, 3H)

[0162] Example #14:2-(2,6-difluorophenyl)-N-(3-ethoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.26;463.2;1H NMR (400 MHz, cd3od) δ = 8.19 (d, J = 2.2 Hz, 1H), 7.76 (d, J = 2.0 Hz, 1H), 7.51 (tt, J = 8.5, 6.3 Hz, 1H), 7.25 (dd, J = 8.2, 2.0 Hz, 1H), 7.16 - 7.04 (m, 3H), 6.56 (d, J = 2.2 Hz, 1H), 5.77 (dp, J = 3.4, 1.6 Hz, 1H), 4.02 (q, J = 7.0 Hz, 2H), 3.25 (q, J = 2.8 Hz, 2H), 2.82 (t, J = 5.8 Hz, 2H), 2.65 (td, J = 6.0, 2.1 Hz, 2H), 2.48 (s, 3H), 1.34 (t, J = 7.0 Hz, 3H)

[0163] Example #15 :2-(2-chloro-6-fluorophenyl)-N-(3,3-dimethyl-2,3-dihydrobenzofuran-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;4.625;410.2;1H NMR (400 MHz, MeOD) δ = 8.24 (d, J = 2.2 Hz, 1H), 7.50 (td, J = 8.3, 5.9 Hz, 1H), 7.40 (dt, J = 8.1, 1.0 Hz, 1H), 7.31 (d, J = 1.9 Hz, 1H), 7.29 - 7.20 (m, 2H), 7.16 (d, J = 8.0 Hz, 1H), 6.59 (d, J = 2.1 Hz, 1H), 4.26 (s, 2H), 1.34 (s, 6H)

[0164] Example #162-(2-chloro-6-fluorophenyl)-N-(3-ethoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 3.325; 479.2; 1H NMR (400 MHz, MeOD) δ = 8.26 (d, J = 2.1 Hz, 1H), 7.71 (d, J = 2.0 Hz, 1H), 7.51 (td, J = 8.3, 5.9 Hz, 1H), 7.41 (dd, J = 8.2, 1.2 Hz, 1H), 7.30 (dd, J = 8.2, 2.1 Hz, 1H), 7.30 - 7.21 (m, 1H), 7.18 (d, J = 8.2 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 5.81 (tt, J = 3.4, 1.6 Hz, 1H), 4.05 (q, J = 7.0 Hz, 2H), 2.90 (t, J = 5.8 Hz, 2H), 2.70 (td, J = 5.8, 2.4 Hz, 2H), 2.55 (s, 3H), 1.35 (t, J = 7.0 Hz, 3H)

[0165] Example #17:2-(2-chloro-6-fluorophenyl)-N-(3-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.366;481.2;1H NMR (400 MHz, MeOD) δ = 8.24 (d, J = 2.1 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.51 (td, J = 8.3, 5.9 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.30 - 7.21 (m, 2H), 7.20 (d, J = 8.3 Hz, 1H), 6.60 (d, J = 2.2 Hz, 1H), 4.06 (q, J = 7.0 Hz, 2H), 3.10 - 3.02 (m, 2H), 3.06 - 2.92 (m, 1H), 2.39 (s, 3H), 2.26 (td, J = 11.8, 3.3 Hz, 2H), 1.82 (qd, J = 12.2, 11.3, 5.0 Hz, 4H), 1.36 (t, J = 7.0 Hz, 3H)

[0166] Example #18:2-(2,6-dichlorophenyl)-N-(3-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 3.991; 497.2; 1H NMR (400 MHz, cd3od) δ = 8.21 (d, J = 2.2 Hz, 1H), 7.57 (d, J = 2.0 Hz, 1H), 7.52 - 7.46 (m, 2H), 7.42 (dd, J = 9.2, 6.8 Hz, 1H), 7.21 (dd, J = 8.3, 2.0 Hz, 1H), 7.16 (d, J = 8.3 Hz, 1H), 6.56 (d, J = 2.2 Hz, 1H), 4.01 (q, J = 6.9 Hz, 2H), 3.06 (d, J = 11.8 Hz, 2H), 2.96 (ddt, J = 11.6, 8.3, 4.2 Hz, 1H), 2.39 (s, 3H), 2.31 (dd, J = 13.2, 10.1 Hz, 2H), 1.87 - 1.69 (m, 4H), 1.31 (t, J = 7.0 Hz, 3H)

[0167] Example #19 :2-(2,6-dichlorophenyl)-N-(3,3-dimethyl-2,3-dihydrobenzofuran-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS C;4.578;426;1H NMR (400 MHz, cd3od) δ = 8.20 (d, J = 2.1 Hz, 1H), 7.51 - 7.44 (m, 2H), 7.44 - 7.33 (m, 1H), 7.26 - 7.15 (m, 2H), 7.11 (d, J = 8.0 Hz, 1H), 6.54 (d, J = 2.2 Hz, 1H), 4.21 (s, 2H), 1.30 (s, 6H)

[0168] Example #20:2-(2,6-difluorophenyl)-N-(3-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 3.219; 465.5; 1H NMR (400 MHz, MeOD) δ = 8.23 ​​(d, J = 2.1 Hz, 1H), 7.76 (d, J = 2.1 Hz, 1H), 7.55 (tt, J = 8.5, 6.3 Hz, 1H), 7.29 (dd, J = 8.3, 2.1 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 7.18 - 7.06 (m, 2H), 6.60 (d, J = 2.1 Hz, 1H), 4.09 (q, J = 7.0 Hz, 2H), 3.22 - 3.14 (m, 2H), 3.05 (tt, J = 11.6, 4.0 Hz, 1H), 2.57 - 2.42 (m, 5H), 1.93 (s, 1H), 1.93 - 1.77 (m, 3H), 1.41 (t, J = 7.0 Hz, 3H)

[0169] Example #21 :2-(2,6-difluorophenyl)-N-(3,3-dimethyl-2,3-dihydrobenzofuran-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;4.52;394.3;1H NMR (400 MHz, MeOD) δ = 8.22 (d, J = 2.2 Hz, 1H), 7.54 (tt, J = 8.5, 6.3 Hz, 1H), 7.37 (d, J = 1.9 Hz, 1H), 7.28 (dd, J = 8.0, 1.9 Hz, 1H), 7.21 - 7.06 (m, 3H), 6.58 (d, J = 2.1 Hz, 1H), 4.27 (s, 2H), 1.35 (s, 6H)

[0170] Example #22:4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-(2,2,2-trifluoroethyl)benzamide;HPLC-MS A;4.037;465.2;1H NMR (400 MHz, MeOD) δ = 8.30 (d, J = 2.2 Hz, 2H), 8.10 - 8.02 (m, 4H), 7.98 - 7.90 (m, 4H), 7.54 (td, J = 8.3, 5.9 Hz, 2H), 7.44 (dt, J = 8.2, 1.0 Hz, 2H), 7.29 (ddd, J = 9.3, 8.4, 1.1 Hz, 2H), 6.66 (d, J = 2.1 Hz, 2H), 4.12 (q, J = 9.4 Hz, 4H)

[0171] Example #23 :N-(tert-butyl)-4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)benzamide; HPLC-MS A; 4.224; 439.2; 1H NMR (400 MHz, MeOD) δ = 8.29 (d, J = 2.1 Hz, 1H), 8.01 - 7.93 (m, 2H), 7.86 - 7.78 (m, 2H), 7.53 (td, J = 8.3, 5.9 Hz, 1H), 7.43 (dt, J = 8.1, 1.0 Hz, 1H), 7.28 (ddd, J = 9.3, 8.4, 1.1 Hz, 1H), 6.65 (d, J = 2.2 Hz, 1H), 1.48 (s, 9H)

[0172] Example #24:4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-ethylbenzamide;HPLC-MS A;3.733;411.2;1H NMR (400 MHz, MeOD) δ = 8.28 (d, J = 2.1 Hz, 1H), 8.07 - 7.94 (m, 2H), 7.91 - 7.83 (m, 2H), 7.52 (td, J = 8.3, 5.9 Hz, 1H), 7.42 (dt, J = 8.2, 1.0 Hz, 1H), 7.26 (ddd, J = 9.3, 8.4, 1.1 Hz, 1H), 6.64 (d, J = 2.1 Hz, 1H), 3.42 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H)

[0173] Example #25 :4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-(tetrahydro-2H-pyran-4-yl)benzamide;HPLC-MS A;3.676;467.2;1H NMR (400 MHz, MeOD) δ = 8.28 (d, J = 2.2 Hz, 1H), 8.03 - 7.94 (m, 2H), 7.92 - 7.84 (m, 2H), 7.52 (td, J = 8.3, 5.9 Hz, 1H), 7.42 (dt, J = 8.1, 1.0 Hz, 1H), 7.26 (ddd, J = 9.3, 8.4, 1.1 Hz, 1H), 6.64 (d, J = 2.2 Hz, 1H), 4.11 (tt, J = 11.2, 4.2 Hz, 1H), 4.00 (ddd, J = 12.2, 4.5, 2.1 Hz, 2H), 3.54 (td, J = 11.9, 2.1 Hz, 2H), 1.91 (ddd, J = 12.6, 4.4, 2.0 Hz, 2H), 1.68 (dtd, J = 12.9, 11.6, 4.5 Hz, 2H)

[0174] Example #26:4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-(2,2,2-trifluoroethyl)benzamide;HPLC-MS A;3.941;449.2;1H NMR (400 MHz, MeOD) δ = 8.27 (d, J = 2.2 Hz, 1H), 8.11 - 8.03 (m, 2H), 7.97 - 7.87 (m, 2H), 7.56 (tt, J = 8.5, 6.3 Hz, 1H), 7.21 - 7.10 (m, 2H), 6.64 (d, J = 2.2 Hz, 1H), 4.11 (q, J = 9.3 Hz, 2H)

[0175] Example #27 :N-(tert-butyl)-4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)benzamide;HPLC-MS A;4.123;423.2;1H NMR (400 MHz, MeOD) δ = 8.26 (d, J = 2.2 Hz, 1H), 8.03 - 7.95 (m, 2H), 7.85 - 7.77 (m, 2H), 7.55 (tt, J = 8.5, 6.3 Hz, 1H), 7.21 - 7.09 (m, 2H), 6.63 (d, J = 2.2 Hz, 1H), 1.47 (s, 9H)

[0176] Example #28 :4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-ethylbenzamide;HPLC-MS A;3.627;395.2;1H NMR (400 MHz, MeOD) δ = 8.26 (d, J = 2.2 Hz, 1H), 8.06 - 7.98 (m, 2H), 7.92 - 7.80 (m, 2H), 7.56 (tt, J = 8.4, 6.3 Hz, 1H), 7.20 - 7.09 (m, 2H), 6.71 - 6.61 (m, 1H), 3.43 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H)

[0177] Example #29 :4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-(tetrahydro-2H-pyran-4-yl)benzamide; HPLC-MS A; 3.574; 451.2; 1H NMR (400 MHz, MeOD) δ = 8.27 (d, J = 2.1 Hz, 1H), 8.07 - 7.96 (m, 2H), 7.93 - 7.85 (m, 2H), 7.56 (tt, J = 8.4, 6.2 Hz, 1H), 7.20 - 7.10 (m, 2H), 6.64 (d, J = 2.2 Hz, 1H), 4.12 (tt, J = 11.3, 4.3 Hz, 1H), 4.01 (dd, J = 12.2, 4.0 Hz, 2H), 3.55 (td, J = 11.9, 2.1 Hz, 2H), 1.92 (dd, J = 12.9, 2.7 Hz, 2H), 1.69 (qd, J = 12.1, 4.5 Hz, 2H)

[0178] Example #30 :N-(4-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-3-ethoxyphenyl)-2-(2,6-dichlorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 3.518; 521.2;

[0179] Example #31 :N-(4-(1-cyclopropylpiperidin-4-yl)-3-ethoxyphenyl)-2-(2,6-dichlorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 3.572; 523.2;

[0180] Example #32:2-(2-chloro-6-fluorophenyl)-N-(3-ethoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.81; 482.2; 1H NMR (400 MHz, methanol-d4) δ = 8.22 (d, J = 2.2 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.48 (td, J = 8.2, 5.9 Hz, 1H), 7.38 (dt, J = 8.2, 1.0 Hz, 1H), 7.29 - 7.19 (m, 2H), 6.98 (d, J = 8.6 Hz, 1H), 6.57 (d, J = 2.2 Hz, 1H), 4.07 (q, J = 7.0 Hz, 2H), 3.16 (s, 4H), 2.88 (s, 4H), 2.54 (s, 3H), 1.38 (t, J = 7.0 Hz, 3H)

[0181] Example #33 2-(2-chloro-6-fluorophenyl)-N-(4-(1-cyclopropylpiperidin-4-yl)-3-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.09; 507.2;

[0182] Example #34:2-(2-chloro-6-fluorophenyl)-N-(4-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-3-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-B;3.06;505.2;1H NMR (400 MHz, methanol-d4) δ = 8.23 ​​(d, J = 2.1 Hz, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.49 (td, J = 8.3, 5.9 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.29 - 7.20 (m, 2H), 7.15 (d, J = 8.2 Hz, 1H), 6.59 (d, 2.97 (t, J = 5.8 Hz, 2H), 2.61 (q, J) = 2.2 Hz, 2H), 2.01 - 1.97 (m, 1H), 1.32 (t, J = 7.0 Hz, 3H), 0.67 - 0.53 (m, 4H)

[0183] Example #35 :2-(4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)-2-methylpropanenitrile;HPLC-B;4.15;407.2;1H NMR (400 MHz, methanol-d4) δ = 8.24 (d, J = 2.1 Hz, 1H), 7.87 (d, J = 8.7 Hz, 2H), 7.55 (d, J = 8.8 Hz, 2H), 7.48 (td, J = 8.3, 5.9 Hz, 1H), 7.41 - 7.36 (m, 1H), 7.23 (ddd, J = 9.3, 8.4, 1.1 Hz, 1H), 6.59 (d, J = 2.2 Hz, 1H), 1.72 (s, 6H

[0184] Example #36:2-(4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-1H-pyrazol-1-yl)-2-methylpropanenitrile; HPLC-B; 3.72; 397.2; 1H NMR (400 MHz, methanol-d4) δ = 8.33 (d, J = 0.7 Hz, 1H), 8.21 (d, J = 2.1 Hz, 1H), 7.96 (d, J = 0.7 Hz, 1H), 7.50 (td, J = 8.2, 5.8 Hz, 1H), 7.41 (dt, J = 8.2, 1.0 Hz, 1H), 7.25 (ddd, J = 9.4, 8.3, 1.1 Hz, 1H), 6.57 (d, J = 2.1 Hz, 1H), 1.98 (s, 6H)

[0185] Example #37 :2-(2,6-difluorophenyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.67; 409.2;

[0186] Example #38 :2-(2,6-difluorophenyl)-N-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.09; 422.2; 1H NMR (400 MHz, methanol-d4) δ = 8.20 (d, J = 2.1 Hz, 1H), 7.72 - 7.65 (m, 2H), 7.51 (tt, J = 8.5, 6.3 Hz, 1H), 7.10 (t, J = 8.1 Hz, 2H), 7.02 (d, J = 9.1 Hz, 2H), 6.55 (d, J = 2.2 Hz, 1H), 3.29 - 3.22 (m, 4H), 2.82 - 2.73 (m, 4H), 2.47 (s, 3H)

[0187] Example #39:1-(4-(4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)piperazin-1-yl)ethan-1-one;HPLC-B;3.93;450.2;1H NMR (400 MHz, methanol-d4) δ = 8.20 (d, J = 2.2 Hz, 1H), 7.71 - 7.65 (m, 2H), 7.51 (tt, J = 8.5, 6.3 Hz, 1H), 7.14 - 7.06 (m, 2H), 7.06 - 7.00 (m, 2H), 6.55 (d, J = 2.2 Hz, 1H), 3.75 - 3.70 (m, 2H), 3.70 - 3.65 (m, 2H), 3.23 - 3.18 (m, 2H), 3.18 - 3.12 (m, 2H), 2.14 (s, 3H)

[0188] Example #40 2-(2,6-difluorophenyl)-N-(3-fluoro-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.87; 427.2;

[0189] Example #41 :2-(2,6-difluorophenyl)-N-(3-methoxy-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.5; 439.2; 1H NMR (400 MHz, methanol-d4) δ = 8.23 ​​(d, J = 2.2 Hz, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.54 (tt, J = 8.5, 6.3 Hz, 1H), 7.33 (dd, J = 8.6, 2.4 Hz, 1H), 7.13 (t, J = 8.2 Hz, 2H), 7.02 (d, J = 8.6 Hz, 1H), 6.59 (d, J = 2.1 Hz, 1H), 3.89 (s, 3H), 3.87 - 3.80 (m, 4H), 3.07 (dd, J = 5.7, 3.6 Hz, 4H)

[0190] Example #42:5-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-2-morpholinobenzonitrile; HPLC-B; 3.78; 434.2; 1H NMR (400 MHz, methanol-d4) δ = 8.23 ​​(d, J = 2.2 Hz, 1H), 8.17 (d, J = 2.6 Hz, 1H), 8.03 (dd, J = 9.0, 2.6 Hz, 1H), 7.53 (tt, J = 8.5, 6.3 Hz, 1H), 7.22 (d, J = 9.0 Hz, 1H), 7.12 (t, J = 8.2 Hz, 2H), 6.59 (d, J = 2.2 Hz, 1H), 3.90 - 3.83 (m, 4H), 3.22 - 3.16 (m, 4H)

[0191] Example #43 2-(2,6-difluorophenyl)-N-(4-(4-morpholinopiperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.41; 492.2;

[0192] Example #44 :2-(2,6-difluorophenyl)-N-(3-isopropoxy-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.89; 467.2; 1H NMR (400 MHz, methanol-d4) δ = 8.21 (d, J = 2.1 Hz, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.53 (tt, J = 8.5, 6.3 Hz, 1H), 7.21 (dd, J = 8.6, 2.4 Hz, 1H), 7.15 - 7.08 (m, 2H), 6.96 (d, J = 8.6 Hz, 1H), 6.57 (d, J = 2.2 Hz, 1H), 4.61 (hept, J = 6.1 Hz, 1H), 3.85 - 3.80 (m, 4H), 3.08 - 3.02 (m, 4H), 1.30 (d, J = 6.0 Hz, 6H)

[0193] Example #45 :N-(4-(4-(tert-butyl)piperazin-1-yl)phenyl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.64; 464.2; 1H NMR (400 MHz, methanol-d4) δ = 8.20 (d, J = 2.2 Hz, 1H), 7.73 - 7.66 (m, 2H), 7.51 (tt, J = 8.5, 6.3 Hz, 1H), 7.16 - 7.06 (m, 2H), 7.05 - 6.99 (m, 2H), 6.55 (d, J = 2.2 Hz, 1H), 3.28 (d, J = 5.2 Hz, 4H), 3.03 - 2.94 (m, 4H), 1.23 (s, 9H)

[0194] Example #46 :2-(2,6-difluorophenyl)-N-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.31; 505.2; 1H NMR (400 MHz, methanol-d4) δ = 8.21 (d, J = 2.2 Hz, 1H), 7.67 (d, J = 9.0 Hz, 2H), 7.52 (tt, J = 8.4, 6.3 Hz, 1H), 7.11 (t, J = 8.1 Hz, 2H), 7.03 (d, J = 9.1 Hz, 2H), 6.56 (d, J = 2.1 Hz, 1H), 3.78 (d, J = 12.6 Hz, 2H), 2.93 - 2.68 (m, 9H), 2.55 (dq, J = 11.4, 3.9 Hz, 1H), 2.49 (s, 3H), 2.01 (d, J = 12.1 Hz, 2H), 1.67 (qd, J = 12.2, 3.9Hz, 2H)

[0195] Example #47:2-(2,6-difluorophenyl)-N-(4-((2S,6R)-2,6-dimethylmorpholino)-3-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 4.17; 481.2; 1H NMR (400 MHz, methanol-d4) δ = 8.20 (d, J = 2.1 Hz, 1H), 7.70 (d, J = 2.4 Hz, 1H), 7.52 (tt, J = 8.5, 6.3 Hz, 1H), 7.25 (dd, J = 8.5, 2.4 Hz, 1H), 7.11 (t, J = 8.2 Hz, 2H), 6.93 (d, J = 8.6 Hz, 1H), 6.56 (d, J = 2.2 Hz, 1H), 4.09 (q, J = 7.0 Hz, 2H), 3.85 (dqd, J = 10.3, 6.3, 2.1 Hz, 2H), 3.35 (s, 1H), 3.32 (d, J = 1.6 Hz, 1H), 2.31 (dd, J = 11.6, 10.1 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H), 1.18 (d, J = 6.3 Hz, 6H)

[0196] Example #48 :2-(2,6-difluorophenyl)-N-(3-isopropoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.83; 480.2;

[0197] Example #49 2-(2,6-difluorophenyl)-N-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.44; 535.2;

[0198] Example #50 :2-(2-fluorophenyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.81; 391.2;

[0199] Example #51 :2-(2-fluorophenyl)-N-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.28; 404.2; 1H NMR (400 MHz, methanol-d4) δ = 8.15 (d, J = 2.1 Hz, 1H), 8.07 (td, J = 7.8, 1.9 Hz, 1H), 7.84 - 7.72 (m, 2H), 7.51 (dddd, J = 8.2, 7.3, 4.8, 1.9 Hz, 1H), 7.32 - 7.19 (m, 2H), 7.06 (d, J = 9.1 Hz, 2H), 6.53 (d, J = 2.1 Hz, 1H), 3.28 - 3.22 (m, 4H), 2.79 - 2.69 (m, 4H), 2.43 (s, 3H)

[0200] Example #52 :1-(4-(4-((2-(2-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)piperazin-1-yl)ethan-1-one; HPLC-B; 3.5; 432.2; 1H NMR (400 MHz, methanol-d4) δ = 8.15 (d, J = 2.1 Hz, 1H), 8.07 (td, J = 7.8, 1.9 Hz, 1H), 7.82 - 7.75 (m, 2H), 7.51 (dddd, J = 8.2, 7.4, 4.8, 1.9 Hz, 1H), 7.32 - 7.19 (m, 2H), 7.10 - 7.02 (m, 2H), 6.53 (d, J = 2.2 Hz, 1H), 3.78 - 3.66 (m, 4H), 3.20 (ddd, J = 21.8, 6.2, 4.1 Hz, 4H), 2.15 (s, 3H)

[0201] Example #53 :N-(3-fluoro-4-morpholinophenyl)-2-(2-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 4.04; 409.2;

[0202] Example #54 :N-(4-(4-(tert-butyl)piperazin-1-yl)phenyl)-2-(2-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.8; 446.2;

[0203] Example #55 :2-(2-fluorophenyl)-N-(3-methoxy-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.64; 421.2; 1H NMR (400 MHz, methanol-d4) δ = 8.17 (d, J = 2.1 Hz, 1H), 8.11 (td, J = 7.8, 1.9 Hz, 1H), 7.84 (d, J = 2.4 Hz, 1H), 7.53 (dddd, J = 8.2, 7.3, 4.9, 1.8 Hz, 1H), 7.39 (dd, J = 8.6, 2.4 Hz, 1H), 7.33 - 7.21 (m, 2H), 7.02 (d, J = 8.6 Hz, 1H), 6.55 (d, J = 2.1 Hz, 1H), 3.93 (s, 3H), 3.87 - 3.83 (m, 4H), 3.09 - 3.02 (m, 4H)

[0204] Example #56 :5-((2-(2-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-2-morpholinobenzonitrile; HPLC-B; 3.94; 416.2;

[0205] Example #57 2-(2-fluorophenyl)-N-(4-(4-morpholinopiperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.68; 474.2;

[0206] Example #58:2-(2-fluorophenyl)-N-(3-isopropoxy-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 4.06; 449.2; 1H NMR (400 MHz, methanol-d4) δ = 8.18 (d, J = 2.2 Hz, 1H), 8.08 (td, J = 7.7, 1.9 Hz, 1H), 7.85 (d, J = 2.4 Hz, 1H), 7.55 (dddd, J = 8.2, 7.4, 4.9, 1.8 Hz, 1H), 7.37 - 7.22 (m, 3H), 7.01 (d, J = 8.6 Hz, 1H), 6.56 (d, J = 2.1 Hz, 1H), 4.74 (hept, J = 6.1 Hz, 1H), 3.88 - 3.83 (m, 4H), 3.11 - 3.06 (m, 4H), 1.37 (d, J = 6.1 Hz, 6H)

[0207] Example #59 :2-(2-fluorophenyl)-N-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.3; 487.2;

[0208] Example #60 :2-(2-fluorophenyl)-N-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-A; 3.06; 517.2;

[0209] Example #61 2-(2-fluorophenyl)-N-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.31; 517.2;

[0210] Example #622-(2,6-difluorophenyl)-N-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.2; 535.2;

[0211] Example #64 :N-(2-(1H-pyrazol-1-yl)benzyl)-8-bromo-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;4.618;483.3;1H NMR (400 MHz, CDCl3) δ = 8.76 (t, J = 6.5 Hz, 1H), 8.03 (s, 1H), 7.93 (dd, J = 1.9, 0.7 Hz, 1H), 7.82 (dd, J = 2.4, 0.7 Hz, 1H), 7.79 (dd, J = 7.3, 1.8 Hz, 1H), 7.48 - 7.33 (m, 4H), 7.11 - 7.00 (m, 2H), 6.56 (t, J = 2.2 Hz, 1H), 4.84 - 4.78 (m, 2H)

[0212] Example #65 :2-(2,6-difluorophenyl)-N-(3,4-dimethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 3.65; 384.2; 1H NMR (400 MHz, chloroform-d) δ = 8.11 (d, J = 2.1 Hz, 1H), 7.72 (d, J = 2.5 Hz, 1H), 7.39 (tt, J = 8.5, 6.2 Hz, 1H), 7.11 (dd, J = 8.6, 2.5 Hz, 1H), 7.05 - 6.96 (m, 2H), 6.89 (d, J = 8.6 Hz, 1H), 6.63 (d, J = 2.2 Hz, 1H), 3.92 (s, 3H), 3.89 (s, 3H)

[0213] Example #66:2-(2,6-difluorophenyl)-N-(1-(1'-methyl-[1,4'-bipiperidine]-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 2.73; 494.2; 1H NMR (400 MHz, chloroform-d) δ = 8.10 - 8.05 (m, 2H), 7.76 (d, J = 0.7 Hz, 1H), 7.41 (s, 1H), 7.04 (t, J = 8.2 Hz, 2H), 6.61 (d, J = 2.2 Hz, 1H), 4.15 (td, J = 10.8, 5.3 Hz, 1H), 3.29 (d, J = 11.7 Hz, 2H), 3.10 (d, J = 11.5 Hz, 2H), 2.55 (s, 8H), 2.22 (s, 3H), 2.11 (d, J = 14.6 Hz, 2H), 2.02 (d, J = 13.8 Hz, 3H)

[0214] Example #67 :2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-C;2.93;481.2;1H NMR (400 MHz, chloroform-d) 8.16 - 8.04 (m, 2H), 7.81 (d, J = 0.7 Hz, 1H), 7.42 (tt, J = 8.4, 6.2 Hz, 1H), 7.11 - 6.98 (m, 2H), 6.62 (d, J = 2.2 Hz, 1H), 4.32 (s, 1H), 4.07 (dd, J = 11.5, 4.4 Hz, 2H), 3.49 - 3.24 (m, 4H), 2.96 (t, J = 11.5 Hz, 1H), 2.78 (s, 2H), 2.47 (s, 2H), 2.22 (s, 3H), 1.94 (d, J = 12.2 Hz, 2H), 1.76 (qd, J = 12.1, 4.3 Hz, 2H)

[0215] Example #68:2-(2,6-difluorophenyl)-N-(1-((1r,4r)-4-morpholinocyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.05; 481.2; 1H NMR (400 MHz, chloroform-d) δ = 8.69 (s, 1H), 8.12 - 8.03 (m, 2H), 7.75 (d, J = 0.8 Hz, 1H), 7.42 (tt, J = 8.4, 6.2 Hz, 1H), 7.05 (t, J = 8.2 Hz, 2H), 6.61 (d, J = 2.2 Hz, 1H), 4.19 - 3.87 (m, 5H), 2.90 (s, 3H), 2.69 (s, 1H), 2.29 (s, 4H), 2.22 (s, 1H), 1.96 - 1.64 (m, 5H)

[0216] Example #69 :N-(2-(1H-pyrazol-1-yl)benzyl)-7-cyclopropyl-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 4.37; 444.2;

[0217] Example #70:2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 2.936; 415; 1H NMR (400 MHz, MeOD) δ = 8.13 (d, J = 2.1 Hz, 1H), 7.53 (tt, J = 8.5, 6.3 Hz, 1H), 7.17 - 7.07 (m, 2H), 6.48 (d, J = 2.1 Hz, 1H), 4.15 (tt, J = 11.7, 4.1 Hz, 1H), 3.78 - 3.71 (m, 4H), 2.75 - 2.68 (m, 4H), 2.47 (tt, J = 11.4, 3.5 Hz, 1H), 2.27 - 2.18 (m, 2H), 2.14 - 2.06 (m, 2H), 1.70 - 1.56 (m, 2H), 1.56 - 1.41 (m, 2H).

[0218] Example #71:2-(2-chloro-6-fluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.5; 497.2; 1H NMR (400 MHz, chloroform-d) δ = 8.21 (d, J = 2.1 Hz, 1H), 8.14 (s, 1H), 7.84 (s, 1H), 7.51 (td, J = 8.3, 5.9 Hz, 1H), 7.41 (dd, J = 8.0, 1.2 Hz, 1H), 7.30 - 7.21 (m, 1H), 6.56 (d, J = 2.2 Hz, 1H), 4.30 (tt, J = 11.1, 4.5 Hz, 1H), 4.03 (dd, J = 11.3, 4.4 Hz, 2H), 3.42 (td, J = 12.0, 1.9 Hz, 3H), 2.88 (tt, J = 11.7, 3.9 Hz, 1H), 2.68 (td, J = 12.1, 2.9 Hz, 2H), 2.28 - 2.04 (m, 4H), 1.90 (ddd, J = 12.1, 4.2, 2.0 Hz, 2H), 1.64 (qd, J = 12.2, 4.6 Hz, 2H)

[0219] Example #72:7-Cyclopropyl-2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.81; 521.2; 1H NMR (400 MHz, chloroform-d) δ = 7.33 (d, J = 0.7 Hz, 1H), 7.03 (d, J = 0.7 Hz, 1H), 6.71 (tt, J = 8.5, 6.3 Hz, 1H), 6.31 (t, J = 8.2 Hz, 2H), 5.42 (s, 1H), 3.53 - 3.41 (m, 1H), 3.21 (dd, J = 11.5, 4.5 Hz, 2H), 2.66 - 2.55 (m, 2H), 2.11 - 2.00 (m, 1H), 1.87 (dd, J = 13.1, 10.2 Hz, 2H), 1.47 - 1.23 (m, 4H), 1.13 - 1.02 (m, 2H), 0.83 (qd, J = 12.2, 4.6 Hz, 2H), 0.34 - 0.15 (m, 3H)

[0220] Example #73 :N-(5-chloro-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.5; 515.2;

[0221] Example #74 2-(2,6-difluorophenyl)-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 2.81; 397.2;

[0222] Example #75:N-(3-chloro-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.22; 515.2;

[0223] Example #76 :2-(2-chloro-6-fluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.06; 431.2;

[0224] Example #77 2-(2,6-difluorophenyl)-8-methyl-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.62; 495.2;

[0225] Example #78 2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-8,9-dihydro-7H-cyclopenta[3,4]pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.75; 521.2;

[0226] Example #79 2-(2,6-difluorophenyl)-7-methyl-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-B; 2.55; 495.2;

[0227] Example #80:N-(1-(1-(cyclopropylmethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;2.935;451.2;1H NMR (400 MHz, MeOD) δ = 8.22 (d, J = 2.2 Hz, 2H), 7.89 (d, J = 0.8 Hz, 1H), 7.57 (tt, J = 8.4, 6.3 Hz, 1H), 7.22 - 7.12 (m, 2H), 6.58 (d, J = 2.1 Hz, 1H), 4.34 (tt, J = 10.1, 4.9 Hz, 1H), 3.43 (d, J = 12.5 Hz, 2H), 2.61 (d, J = 6.9 Hz, 4H), 2.29 - 2.14 (m, 4H), 1.06 - 0.94 (m, 1H), 0.71 - 0.60 (m, 2H), 0.33 - 0.24 (m, 2H).

[0228] Example #81 :2-(2,6-difluorophenyl)-N-(1-(1-(2-fluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS C;3.414;443.2;1H NMR (400 MHz, MeOD) δ = 8.23 ​​- 8.17 (m, 2H), 7.88 (s, 1H), 7.57 (tt, J = 8.5, 6.3 Hz, 1H), 7.17 (t, J = 8.3 Hz, 2H), 6.57 (d, J = 2.1 Hz, 1H), 4.70 - 4.64 (m, 1H), 4.58 - 4.52 (m, 1H), 4.21 (tt, J = 10.2, 4.8 Hz, 1H), 3.13 (d, J = 12.2 Hz, 2H), 2.78 (dt, J = 28.6, 4.8 Hz, 2H), 2.35 (td, J = 11.8, 3.2 Hz, 2H), 2.17 - 2.03 (m, 4H)

[0229] Example #82:Methyl-4-(4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate;HPLC-MS A;3.709;455.2;1H NMR (400 MHz, cd3od) δ = 8.16 (d, J = 2.1 Hz, 1H), 8.13 (s, 1H), 7.84 (s, 1H), 7.52 (tt, J = 8.4, 6.3 Hz, 1H), 7.11 (t, J = 8.2 Hz, 2H), 6.52 (d, J = 2.1 Hz, 1H), 4.35 (tt, J = 11.5, 4.1 Hz, 1H), 4.19 (d, J = 12.6 Hz, 2H), 3.69 (s, 3H), 3.05 - 2.94 (m, 2H), 2.06 (d, J = 12.0 Hz, 2H), 1.89 (qd, J = 12.4, 4.4 Hz, 2H)

[0230] Example #83:N-(1-(1-cyclopropylpiperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 3.591; 437.2; 1H NMR (400 MHz, cd3od) δ = 8.16 (d, J = 2.1 Hz, 1H), 8.13 (s, 1H), 7.82 (s, 1H), 7.52 (tt, J = 8.4, 6.3 Hz, 1H), 7.11 (t, J = 8.3 Hz, 2H), 6.52 (d, J = 2.1 Hz, 1H), 4.19 (tt, J = 11.5, 4.5 Hz, 1H), 3.16 (d, J = 12.5 Hz, 2H), 2.46 (td, J = 12.1, 2.4 Hz, 2H), 2.09 (d, J = 10.9 Hz, 2H), 1.97 (qd, J = 13.6, 12.7, 4.0 Hz, 2H), 1.75 (tt, J = 6.9, 3.5 Hz, 1H), 0.52 (td, J = 6.3, 5.8, 3.5 Hz, 2H), 0.45 (q, J = 4.1 Hz, 2H)

[0231] Example #84:2-(2,6-difluorophenyl)-N-(1-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;2.753;453.2;1H NMR (400 MHz, cd3od) δ = 8.17 (d, J = 2.1 Hz, 1H), 8.14 (s, 1H), 7.83 (d, J = 0.6 Hz, 1H), 7.52 (tt, J = 8.4, 6.3 Hz, 1H), 7.16 - 7.08 (m, 2H), 6.53 (d, J = 2.1 Hz, 1H), 4.67 (t, J = 6.7 Hz, 2H), 4.59 (t, J = 6.3 Hz, 2H), 4.18 (s, 1H), 3.53 (p, J = 6.6 Hz, 1H), 2.88 (d, J = 5.9 Hz, 2H), 2.15 - 1.99 (m, 6H)

[0232] Example #85 :2-(2,6-difluorophenyl)-N-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 4.180; 479.2; 1H NMR (400 MHz, MeOD) δ = 8.21 (d, J = 2.1 Hz, 1H), 8.17 (s, 1H), 7.89 (s, 1H), 7.57 (tt, J = 8.5, 6.3 Hz, 1H), 7.16 (t, J = 8.3 Hz, 2H), 6.57 (d, J = 2.1 Hz, 1H), 4.23 - 4.13 (m, 1H), 3.20 - 3.07 (m, 4H), 2.65 - 2.54 (m, 2H), 2.09 (td, J = 8.6, 7.4, 3.7 Hz, 4H)

[0233] Example #86:N-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;2.928;461.2;1H NMR (400 MHz, MeOD) δ = 8.24 - 8.17 (m, 2H), 7.89 (s, 1H), 7.57 (tt, J = 8.5, 6.3 Hz, 1H), 7.22 - 7.11 (m, 2H), 6.57 (d, J = 2.1 Hz, 1H), 6.07 (t, J = 55.5 Hz, 1H), 4.24 (s, 1H), 3.19 (s, 2H), 2.94 (s, 2H), 2.58 (s, 2H), 2.14 (d, J = 8.5 Hz, 4H)

[0234] Example #87 :N-(1-(1-(but-3-en-1-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS B;2.626;451.2;1H NMR (400 MHz, MeOD) δ = 8.23 ​​- 8.18 (m, 2H), 7.88 (s, 1H), 7.57 (tt, J = 8.5, 6.3 Hz, 1H), 7.17 (t, J = 8.3 Hz, 2H), 6.58 (d, J = 2.1 Hz, 1H), 5.85 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.20 - 5.04 (m, 2H), 4.28 (tt, J = 10.5, 4.4 Hz, 1H), 3.23 (d, J = 12.0 Hz, 2H), 2.71 - 2.61 (m, 2H), 2.52 - 2.32 (m, 4H), 2.15 (dq, J = 21.0, 11.1, 9.4Hz, 4H)

[0235] Example #88:2-(2,6-difluorophenyl)-4-((1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile; HPLC-MS A; 2.962; 506.2; 1H NMR (400 MHz, MeOD) δ = 8.55 (s, 1H), 8.21 (d, J = 0.6 Hz, 1H), 7.88 (d, J = 0.7 Hz, 1H), 7.61 (tt, J = 8.5, 6.2 Hz, 1H), 7.25 - 7.14 (m, 2H), 4.30 - 4.18 (m, 1H), 4.03 (dd, J = 11.4, 4.4 Hz, 2H), 3.43 (td, J = 11.9, 1.8 Hz, 2H), 3.21 (d, J = 12.0 Hz, 2H), 2.72 - 2.62 (m, 1H), 2.49 (t, J = 11.4 Hz, 2H), 2.19 (d, J = 12.3 Hz, 2H), 2.07 (qd, J = 12.2, 3.8 Hz, 2H), 1.88 (d, J = 11.6 Hz, 2H), 1.62 (qd, J = 12.2, 4.5 Hz, 2H)

[0236] Example #89:8-Chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 3.636; 449.2; 1H NMR (400 MHz, MeOD) δ = 8.15 (s, 1H), 7.55 (tt, J = 8.4, 6.3 Hz, 1H), 7.13 (t, J = 8.0 Hz, 2H), 4.16 (tt, J = 11.8, 4.1 Hz, 1H), 3.72 (t, J = 4.7 Hz, 4H), 2.63 (t, J = 4.7 Hz, 4H), 2.40 - 2.30 (m, 1H), 2.19 (d, J = 12.3 Hz, 2H), 2.07 (d, J = 12.6 Hz, 2H), 1.69 - 1.55 (m, 2H), 1.45 (q, J = 11.4, 10.6 Hz, 2H)

[0237] Example #90:2-(2,6-difluorophenyl)-8-phenyl-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.496;557.4;1H NMR (400 MHz, MeOD) δ = 8.61 (d, J = 1.6 Hz, 1H), 8.24 (s, 1H), 8.12 - 8.05 (m, 2H), 7.89 (d, J = 0.7 Hz, 1H), 7.63 - 7.51 (m, 1H), 7.43 (t, J = 7.7 Hz, 2H), 7.27 (d, J = 7.3 Hz, 1H), 7.18 (t, J = 8.2 Hz, 2H), 4.21 (t, J = 11.5 Hz, 1H), 4.03 (dd, J = 11.3, 4.3 Hz, 2H), 3.44 (t, J = 11.6 Hz, 2H), 3.18 (d, J = 11.9 Hz, 2H), 2.61 (t, J = 11.6 Hz, 1H), 2.42 (q, J = 12.9, 12.4 Hz, 2H), 2.19 (d, J = 13.0 Hz, 2H), 2.07 (t, J = 10.5 Hz, 2H), 1.91 - 1.83 (m, 2H), 1.67 - 1.54 (m, 2H)

[0238] Example #912-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)-8-phenylpyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 4.353; 491.2; 1H NMR (400 MHz, MeOD) δ = 8.52 (s, 1H), 8.06 - 8.00 (m, 2H), 7.59 - 7.48 (m, 1H), 7.40 (t, J = 7.8 Hz, 2H), 7.24 (td, J = 7.3, 1.3 Hz, 1H), 7.13 (t, J = 8.0 Hz, 2H), 4.16 (dd, J = 15.8, 7.5 Hz, 1H), 3.72 (t, J = 4.6 Hz, 4H), 2.63 (t, J = 4.7 Hz, 4H), 2.36 (t, J = 11.5 Hz, 1H), 2.23 (d, J = 12.5 Hz, 2H), 2.08 (d, J = 12.4 Hz, 2H), 1.62 (q, J = 12.8 Hz, 2H), 1.48 (t, J = 12.0 Hz, 2H)

[0239] Example #928-Chloro-2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 3.406; 515.2; 1H NMR (400 MHz, MeOD) δ = 8.23 ​​(s, 1H), 8.19 (d, J = 0.7 Hz, 1H), 7.87 (d, J = 0.7 Hz, 1H), 7.58 (tt, J = 8.5, 6.3 Hz, 1H), 7.23 - 7.12 (m, 2H), 4.26 (tt, J = 11.3, 4.3 Hz, 1H), 4.03 (dd, J = 11.5, 4.5 Hz, 2H), 3.43 (td, J = 11.9, 1.9 Hz, 2H), 3.25 (d, J = 12.1 Hz, 2H), 2.73 (ddt, J = 11.5, 7.6, 3.8 Hz, 1H), 2.60 - 2.50 (m, 2H), 2.20 (d, J = 12.4 Hz, 2H), 2.09 (qd, J = 12.1, 3.9 Hz, 2H), 1.93 - 1.85 (m, 2H), 1.63 (qd, J = 12.2, 4.5 Hz, 2H)

[0240] Example #93:2-(2,6-difluorophenyl)-4-(((1r,4r)-4-morpholinocyclohexyl)amino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile;HPLC-MS C;3.002;440.2;1H NMR (400 MHz, MeOD) δ = 8.46 (s, 1H), 7.56 (tt, J = 8.5, 6.3 Hz, 1H), 7.19 - 7.08 (m, 2H), 4.18 (tt, J = 11.8, 4.1 Hz, 1H), 3.75 - 3.68 (m, 4H), 2.67 - 2.60 (m, 4H), 2.36 (tt, J = 11.4, 3.5 Hz, 1H), 2.23 - 2.15 (m, 2H), 2.08 (d, J = 12.7 Hz, 2H), 1.71 - 1.56 (m, 2H), 1.45 (qd, J = 12.9, 3.2 Hz, 2H)

[0241] Example #94 8-Bromo-2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 3.302; 559.2; 1H NMR (400 MHz, MeOD) δ = 8.23 ​​(s, 1H), 8.19 (s, 1H), 7.87 (s, 1H), 7.57 (tt, J = 8.5, 6.3 Hz, 1H), 7.16 (t, J = 8.2 Hz, 2H), 4.30 (td, J = 11.0, 5.4 Hz, 1H), 4.05 (dt, J = 11.3, 5.8 Hz, 2H), 3.44 (dd, J = 12.4, 10.6 Hz, 2H), 3.29 (s, 2H), 2.88 - 2.78 (m, 1H), 2.64 (t, J = 11.7 Hz, 2H), 2.23 (d, J = 12.9 Hz, 2H), 2.19 - 2.05 (m, 2H), 1.91 (d, J = 12.5 Hz, 2H), 1.65 (qd, J = 12.2, 4.6 Hz, 2H)

[0242] Example #95 :8-Bromo-2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS C; 3.320; 493.2; 1H NMR (400 MHz, MeOD) δ = 8.15 (s, 1H), 7.54 (tt, J = 8.5, 6.3 Hz, 1H), 7.18 - 7.07 (m, 2H), 4.15 (tt, J = 11.8, 4.1 Hz, 1H), 3.76 - 3.69 (m, 4H), 2.69 - 2.62 (m, 4H), 2.39 (tt, J = 11.4, 3.5 Hz, 1H), 2.20 (d, J = 12.6 Hz, 2H), 2.08 (d, J = 12.5 Hz, 2H), 1.62 (qd, J = 12.7, 3.1 Hz, 2H), 1.46 (qd, J = 13.1, 3.2 Hz, 2H)

[0243] Example #96 :8-Chloro-2-(2,6-difluorophenyl)-N-(1-(1'-methyl-[1,4'-bipiperidine]-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 2.678; 528.2; 1H NMR (400 MHz, MeOD) δ = 8.22 (s, 1H), 8.18 (s, 1H), 7.88 (s, 1H), 7.57 (ddd, J = 14.8, 8.5, 6.3 Hz, 1H), 7.16 (t, J = 8.2 Hz, 2H), 4.28 (td, J = 11.0, 5.5 Hz, 1H), 3.52 (d, J = 12.4 Hz, 2H), 3.27 (d, J = 11.9 Hz, 2H), 3.00 (t, J = 13.1 Hz, 2H), 2.91 (d, J = 11.6 Hz, 1H), 2.83 (s, 3H), 2.71 - 2.59 (m, 2H), 2.26 - 2.09 (m, 6H), 1.89 (q, J = 14.9, 13.0 Hz, 2H).

[0244] Example #97 :N-(4-(4-(tert-butyl)piperazin-1-yl)phenyl)-8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.315;498.2;1H NMR (400 MHz, MeOD) δ = 8.22 (s, 1H), 7.68 (d, J = 9.0 Hz, 2H), 7.53 (ddd, J = 14.8, 8.5, 6.3 Hz, 1H), 7.12 (t, J = 8.1 Hz, 2H), 7.04 (d, J = 9.1 Hz, 2H), 3.30 (t, J = 5.0 Hz, 4H), 2.99 (t, J = 5.0 Hz, 4H), 1.24 (d, J = 2.6 Hz, 9H)

[0245] Example #98 :(4-((8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)(morpholino)methanone;HPLC-MS A;3.893;471.2;1H NMR (400 MHz, MeOD) δ = 8.28 (s, 1H), 8.00 (d, J = 8.7 Hz, 2H), 7.60 - 7.55 (m, 1H), 7.55 - 7.49 (m, 2H), 7.14 (t, J = 8.2 Hz, 2H), 3.89 - 3.53 (m, 8H)

[0246] Example #99:8-chloro-N-(1-(1-cyclopropylpiperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 3.044; 471.2; 1H NMR (400 MHz, MeOD) δ = 8.22 (s, 1H), 8.16 (s, 1H), 7.86 (s, 1H), 7.57 (ddd, J = 14.8, 8.5, 6.3 Hz, 1H), 7.16 (t, J = 8.2 Hz, 2H), 4.25 (tt, J = 11.4, 4.3 Hz, 1H), 3.22 (d, J = 12.4 Hz, 2H), 2.54 (td, J = 12.1, 2.7 Hz, 2H), 2.13 (d, J = 13.8 Hz, 2H), 2.05 (dd, J = 11.9, 3.9 Hz, 2H), 1.83 (ddd, J = 10.5, 6.8, 3.8 Hz, 1H), 0.61 - 0.48 (m, 4H)

[0247] Example #100 :8-chloro-N-(1-(1-(cyclopropylmethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.083;485.2;1H NMR (400 MHz, MeOD) δ = 8.21 (d, J = 10.0 Hz, 2H), 7.89 (s, 1H), 7.57 (tt, J = 8.4, 6.3 Hz, 1H), 7.16 (t, J = 8.2 Hz, 2H), 4.45 (p, J = 7.6 Hz, 1H), 3.60 (d, J = 13.3 Hz, 2H), 3.01 - 2.89 (m, 2H), 2.85 (d, J = 7.1 Hz, 2H), 2.30 (q, J = 5.5, 4.6 Hz, 4H), 1.16 - 1.02 (m, 1H), 0.78 - 0.69 (m, 2H), 0.41 - 0.34 (m, 2H)

[0248] Example #101 :8-Chloro-2-(2-chloro-6-fluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.078;531.2;1H NMR (400 MHz, MeOD) δ = 8.24 (s, 1H), 8.16 (s, 1H), 7.85 (s, 1H), 7.57 - 7.50 (m, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.31 - 7.24 (m, 1H), 4.35 (td, J = 10.7, 4.5 Hz, 1H), 4.09 - 4.01 (m, 2H), 3.49 - 3.36 (m, 4H), 2.99 (tt, J = 11.6, 3.8 Hz, 1H), 2.78 (td, J = 11.9, 3.2 Hz, 2H), 2.29 - 2.10 (m, 4H), 1.94 (dd, J = 12.3, 2.8 Hz, 2H), 1.68 (qd, J = 12.2, 4.6 Hz, 2H)

[0249] Example #102:8-Chloro-2-(2,6-dichlorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.209;547.2;1H NMR (400 MHz, MeOD) δ = 8.25 (s, 1H), 8.12 (s, 1H), 7.83 (s, 1H), 7.58 - 7.54 (m, 2H), 7.49 (dd, J = 9.3, 6.7 Hz, 1H), 4.33 (td, J = 10.9, 5.4 Hz, 1H), 4.04 (dd, J = 11.5, 4.5 Hz, 2H), 3.49 - 3.39 (m, 2H), 3.38 - 3.34 (m, 2H), 2.91 (ddt, J = 11.7, 7.9, 3.8 Hz, 1H), 2.70 (td, J = 11.9, 3.0 Hz, 2H), 2.28 - 2.07 (m, 4H), 1.96 - 1.88 (m, 2H), 1.66 (qd, J = 12.2, 4.6 Hz, 2H)

[0250] Example #103 :8-chloro-2-(2,6-difluorophenyl)-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 3.004; 431.2; 1H NMR (400 MHz, MeOD) δ = 8.23 ​​(s, 1H), 8.21 (s, 1H), 7.90 (s, 1H), 7.58 (ddd, J = 14.7, 8.5, 6.3 Hz, 1H), 7.16 (t, J = 8.2 Hz, 2H), 4.59 - 4.46 (m, 1H), 3.56 - 3.45 (m, 2H), 3.21 - 3.10 (m, 2H), 2.36 - 2.16 (m, 4H)

[0251] Example #104:8-Chloro-2-(2,6-difluorophenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.780;362.2;1H NMR (400 MHz, MeOD) δ = 8.22 (s, 1H), 8.07 (s, 1H), 7.83 (d, J = 0.7 Hz, 1H), 7.57 (tt, J = 8.5, 6.3 Hz, 1H), 7.21 - 7.10 (m, 2H), 3.90 (s, 3H)

[0252] Example #105 :8-Chloro-2-(2,6-difluorophenyl)-N-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.932;362.2;1H NMR (400 MHz, MeOD) δ = 8.24 (s, 1H), 7.63 - 7.49 (m, 2H), 7.20 - 7.08 (m, 2H), 6.78 (d, J = 2.4 Hz, 1H), 3.87 (s, 3H)

[0253] Example #106 8-Chloro-2-(2,6-difluorophenyl)-N-(1-methyl-1H-imidazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS A; 3.432; 362.2;

[0254] Example #107:2-((4-((8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)pentyl)(ethyl)amino)ethan-1-ol;HPLC-MS B;2.596;439.3;1H NMR (400 MHz, MeOD) δ = 8.15 (s, 1H), 7.54 (tt, J = 8.5, 6.3 Hz, 1H), 7.16 - 7.08 (m, 2H), 4.53 - 4.43 (m, 1H), 3.67 (t, J = 6.0 Hz, 2H), 2.78 (q, J = 7.6, 7.0 Hz, 6H), 1.92 (s, 1H), 1.85 - 1.75 (m, 1H), 1.75 - 1.63 (m, 3H), 1.38 (d, J = 6.7 Hz, 3H), 1.09 (t, J = 7.2 Hz, 3H)

[0255] Example #108 :(1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclohexane-1,4-diamine;HPLC-MS A;2.893;379.2;1H NMR (400 MHz, MeOD) δ = 8.16 (s, 1H), 7.55 (tt, J = 8.5, 6.3 Hz, 1H), 7.17 - 7.08 (m, 2H), 4.21 (tt, J = 11.7, 4.0 Hz, 1H), 3.14 (tt, J = 11.6, 3.9 Hz, 1H), 2.18 (dd, J = 36.1, 11.5 Hz, 4H), 1.79 - 1.49 (m, 5H)

[0256] Example #109:(1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine;HPLC-MS A;2.975;407.2;1H NMR (400 MHz, MeOD) δ = 8.15 (s, 1H), 7.55 (tt, J = 8.5, 6.3 Hz, 1H), 7.17 - 7.07 (m, 2H), 4.21 (td, J = 11.2, 4.0 Hz, 1H), 3.03 (d, J = 13.5 Hz, 1H), 2.70 (s, 6H), 2.32 - 2.07 (m, 4H), 1.78 - 1.57 (m, 4H)

[0257] Example #110 :8-Chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(piperidin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.146;447.2;1H NMR (400 MHz, MeOD) δ = 8.15 (s, 1H), 7.54 (tt, J = 8.5, 6.3 Hz, 1H), 7.16 - 7.05 (m, 2H), 4.25 - 4.11 (m, 1H), 2.93 (s, 4H), 2.83 (s, 1H), 2.18 (dd, J = 53.0, 8.3 Hz, 4H), 1.76 (p, J = 5.8 Hz, 4H), 1.64 (dt, J = 20.2, 9.1 Hz, 6H)

[0258] Example #111 2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)-8-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS B; 2.91; 483.2;

[0259] Example #112:(1s,4s)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclohexane-1,4-diamine; HPLC-MS A; 2.927; 379.2;

[0260] Example #113 :8-Chloro-2-(2,6-difluorophenyl)-N-((1s,4s)-4-(piperidin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS A;3.186;447.3;1H NMR (400 MHz, MeOD) δ = 8.19 (s, 1H), 7.54 (tt, J = 8.5, 6.3 Hz, 1H), 7.17 - 7.06 (m, 2H), 4.41 (q, J = 3.6 Hz, 1H), 2.86 (s, 4H), 2.73 (s, 1H), 2.28 (q, J = 8.5, 5.7 Hz, 2H), 1.91 - 1.67 (m, 10H), 1.63 - 1.52 (m, 2H)

[0261] Example #114 :(1s,4s)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine;HPLC-MS A;3.013;407.2;1H NMR (400 MHz, MeOD) δ = 8.20 (s, 1H), 7.54 (tt, J = 8.4, 6.3 Hz, 1H), 7.18 - 7.07 (m, 2H), 4.44 (p, J = 3.5 Hz, 1H), 3.16 (td, J = 9.3, 4.7 Hz, 1H), 2.81 (s, 6H), 2.34 - 2.26 (m, 2H), 1.96 - 1.79 (m, 6H)

[0262] Example #1152-(2,6-difluorophenyl)-N-(1-methyl-1H-pyrazol-4-yl)-8-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS B; 3.81; 396.2;

[0263] Example #116 :(1R,3R)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclopentane-1,3-diamine; HPLC-MS C; 3.07; 365.2;

[0264] Example #117 :N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclopentane-1,3-diamine; HPLC-MS C; 3.09; 365.2;

[0265] Example #118 :(1r,4r)-N1-(2-(2,6-difluorophenyl)-8-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclohexane-1,4-diamine; HPLC-MS B; 2.84; 413.2;

[0266] Example #119:(1R,3R)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N3,N3-dimethylcyclopentane-1,3-diamine;HPLC-MS C;3.16;393.2;1H NMR (400 MHz, methanol-d4) δ = 8.14 (s, 1H), 7.52 (tt, J = 8.5, 6.3 Hz, 1H), 7.14 - 7.07 (m, 2H), 4.74 (p, J = 7.6 Hz, 1H), 3.42 (p, J = 8.2 Hz, 1H), 2.62 (s, 6H), 2.32 (dddd, J = 22.0, 14.8, 7.4, 2.6 Hz, 2H), 2.22 (t, J = 7.7 Hz, 2H), 1.94 (s, 3H, AcOH), 1.93 - 1.84 (m, 1H), 1.70 (tt, J = 11.5, 9.2 Hz, 1H)

[0267] Example #120 :(1r,4r)-N1-(2-(2,6-difluorophenyl)-8-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine; HPLC-MS B; 2.9; 441.2;

[0268] Example #124 :(1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4-(2-methoxyethyl)cyclohexane-1,4-diamine; HPLC-MS B; 2.69; 437.2;

[0269] Example #125 :(1S,3R)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclopentane-1,3-diamine; HPLC-MS B; 2.52; 365.2;

[0270] Example #126:(1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4-(2-fluoroethyl)cyclohexane-1,4-diamine;HPLC-MS B;2.63;425.2;1H NMR (400 MHz, methanol-d4) δ = 8.14 (s, 1H), 7.53 (tt, J = 8.5, 6.3 Hz, 1H), 7.15 - 7.05 (m, 2H), 4.76 - 4.70 (m, 1H), 4.63 - 4.58 (m, 1H), 4.19 (ddd, J = 11.8, 7.9, 4.0 Hz, 1H), 3.75 (dt, J = 36.1, 5.4 Hz, 1H), 3.25 - 3.19 (m, 1H), 3.15 - 3.11 (m, 1H), 3.06 - 2.91 (m, 1H), 2.20 (t, J = 10.9 Hz, 4H), 1.74 - 1.40 (m, 4H)

[0271] Example #127 :2-(((1r,4r)-4-((8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)cyclohexyl)amino)ethan-1-ol; HPLC-MS B; 2.58; 423.2; 1H NMR (400 MHz, methanol-d4) δ = 8.14 (s, 1H), 7.53 (tt, J = 8.5, 6.3 Hz, 1H), 7.15 - 7.07 (m, 2H), 4.20 (ddt, J = 11.7, 8.0, 3.8 Hz, 1H), 3.85 - 3.74 (m, 2H), 3.18 - 3.02 (m, 3H), 2.23 (d, J = 10.5 Hz, 4H), 1.75 - 1.47 (m, 4H)

[0272] Example #128:(1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4-(3-fluoropropyl)cyclohexane-1,4-diamine;HPLC-MS B;2.7;439.2;1H NMR (400 MHz, methanol-d4) δ = 8.14 (s, 1H), 7.53 (tt, J = 8.5, 6.3 Hz, 1H), 7.15 - 7.06 (m, 2H), 4.64 (t, J = 5.5 Hz, 1H), 4.52 (t, J = 5.5 Hz, 1H), 4.20 (ddt, J = 11.7, 7.7, 3.7 Hz, 1H), 3.25 - 3.11 (m, 4H), 2.25 (d, J = 10.1 Hz, 4H), 2.15 - 2.01 (m, 2H), 1.77 - 1.49 (m, 4H)

[0273] Example #129 :(1r,3r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclobutane-1,3-diamine; HPLC-MS A; 2.87; 351.2;

[0274] Example #130 :(1r,3r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N3,N3-dimethylcyclobutane-1,3-diamine; HPLC-MS B; 2.49; 379.2;

[0275] Example #131 :(1r,4r)-N1-(8-chloro-2-(2,4,6-trifluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine; HPLC-MS B; 2.76; 425.2;

[0276] Example #132:(1r,4r)-N1-(8-chloro-2-(2,6-difluoro-4-methylphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine; HPLC-MS B; 2.84; 421.2;

[0277] Example #133 2-(((1r,4r)-4-((8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)cyclohexyl)(methyl)amino)ethan-1-ol; HPLC-MS B; 2.56; 437.2;

[0278] Example #134 3-({4-[8-chloro-2-(2,6-difluoro-phenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-ylamino]-cyclohexyl}-methyl-amino)-propan-1-ol; HPLC-MS B; 2.64; 451.2;

[0279] Example #135 :(1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4-(3-fluoropropyl)-N4-methylcyclohexane-1,4-diamine; HPLC-MS B; 2.75; 453.2;

[0280] Example #138:8-Chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(pyrrolidin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-MS B; 2.69; 433.20; 1H NMR (600 MHz, methanol-d4) δ 8.14 (s, 1H), 7.53 (tt, J = 8.5, 6.3 Hz, 1H), 7.11 (t, J = 8.0 Hz, 2H), 4.19 (tt, J = 11.6, 3.8 Hz, 1H), 3.24 (s, 4H), 2.98 (t, J = 11.9 Hz, 1H), 2.25 (td, J = 11.2, 5.8 Hz, 4H), 2.08 - 1.96 (m, 4H), 1.73 - 1.53 (m, 4H)

[0281] Example #139 :2-(2,6-difluorophenyl)-8-ethynyl-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-C;3.52;439.2;1H NMR (800 MHz, methanol-d4) δ 8.20 (s, 1H), 7.60 - 7.45 (m, 1H), 7.17 - 7.00 (m, 2H), 4.19 (brs, 1H), 3.88 (brs, 3H), 3.63 (s, 1H), 3.26 - 2.92 (m, 2H), 2.25 (dd, J = 40.5, 11.4 Hz, 4H), 1.67 (dt, J = 23.5, 12.6 Hz, 4H), 1.36 - 1.25 (m, 2H).

[0282] Example #140:2-(2,6-difluorophenyl)-8-iodo-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; HPLC-C; 3.84; 541.2; 1H NMR (800 MHz, methanol-d4) δ 8.12 (s, 1H), 7.52 (ddd, J = 8.5, 6.3, 2.2 Hz, 1H), 7.17 - 6.99 (m, 2H), 4.16 - 4.07 (m, 1H), 3.70 (t, J = 4.7 Hz, 3H), 2.62 (t, J = 4.7 Hz, 3H), 2.34 (s, 1H), 2.17 (dd, J = 12.9, 4.0 Hz, 2H), 2.04 (dd, J = 12.9, 4.0 Hz, 2H), 1.66 - 1.53 (m, 2H), 1.48 - 1.37 (m, 2H)

[0283] Example #141 :8-Chloro-2-(2,6-difluorophenyl)-N-(1-methylpiperidin-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS B;2.45;379.20;1H NMR (400 MHz, methanol-d4) δ 8.14 (s, 1H), 7.52 (tt, J = 8.5, 6.4 Hz, 1H), 7.15 - 7.06 (m, 2H), 4.24 (ddd, J = 15.6, 11.2, 4.3 Hz, 1H), 3.09 (d, J = 12.1 Hz, 2H), 2.45 (m, 5H, CH3+2CH), 2.14 (d, J = 13.2 Hz, 2H), 1.98 - 1.86 (m, 2H)

[0284] Example #142 :N-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)quinuclidin-4-amine; HPLC-MS B; 2.59; 391.20;

[0285] Example #143:8-Chloro-2-(2,6-difluorophenyl)-N-((1s,4s)-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS B;2.359;462.2;1H NMR (600 MHz, cd3od) δ 8.15 (s, 1H), 7.52 (tt, J = 8.5, 6.3 Hz, 1H), 7.13 - 7.07 (m, 2H), 4.32 (tt, J = 7.1, 3.7 Hz, 1H), 2.65 (t, J = 5.3 Hz, 5H), 2.40 (s, 3H), 2.40 - 2.33 (m, 2H), 2.14 - 2.07 (m, 2H), 1.92 (s, 2H), 1.85 (dt, J = 12.4, 8.9 Hz, 2H), 1.80 - 1.70 (m, 4H)

[0286] Example #144 :8-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS B;2.3;463.2;1H NMR (600 MHz, cd3od) δ 8.13 (s, 1H), 7.52 (tt, J = 8.4, 6.3 Hz, 1H), 7.13 - 7.08 (m, 2H), 4.14 (tt, J = 11.8, 4.1 Hz, 1H), 2.78 (d, J = 29.0 Hz, 8H), 2.56 (tq, J = 11.0, 4.0 Hz, 1H), 2.47 (s, 3H), 2.21 - 2.14 (m, 2H), 2.04 (dt, J = 12.5, 3.3 Hz, 2H), 1.61 (qd, J = 12.8, 3.2 Hz, 2H), 1.49 (qd, J = 12.7, 3.1 Hz, 2H)

[0287] Example #145:8-Chloro-2-(2,6-difluorophenyl)-N-((4,6-dimethylpyridin-3-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS B;2.66;401.00;1H NMR (600 MHz, methanol-d4) δ 8.37 (s, 1H), 8.15 (s, 1H), 7.52 (tt, J = 8.4, 6.3 Hz, 1H), 7.16 (s, 1H), 7.13 - 7.06 (m, 2H), 4.84 (s, 2H), 2.46 (s, 3H), 2.41 (d, J = 0.7 Hz, 3H)

[0288] Example #146 :8-Chloro-2-(2,6-difluorophenyl)-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine;HPLC-MS B;2.80;373.00;1H NMR (600 MHz, methanol-d4) δ 8.63 (d, J = 2.2 Hz, 1H), 8.45 (dd, J = 5.0, 1.6 Hz, 1H), 8.16 (s, 1H), 7.95 (dt, J = 7.9, 1.9 Hz, 1H), 7.53 (tt, J = 8.5, 6.3 Hz, 1H), 7.42 (ddd, J = 7.9, 4.9, 0.9 Hz, 1H), 7.14 - 7.07 (m, 2H), 4.86 (s, 2H)

[0289] Biological Data Assay protocol for measuring inhibitory activity Test compounds were evaluated at 12 concentrations in a 1:3 dilution series starting at a highest concentration of 5 μM.

[0290] In a white 384 microplate (Greiner bio-one, Austria, #784904), 2 microL of 3x concentrated, final concentration (fc) 6 nM, CDK9 / cyclin T1 (ProQinase / Reaction Biology, USA, #0371-0345-1, LOT.:012) in 1x kinase buffer was added, followed by 2 microL of compounds (3x concentrated, fc 1.66%, in DMSO / H2O) and incubated for 10 min at room temperature (RT). Then 2 microL of substrate / ATP mix (3xPDKtide fc40 microM; SignalChem Biotech, Canada; via Biozol, Eching, Germany; #P10-58, LOT.:L2230-7, and 3xUltraPure ATP fc10 microM (ADP Glo Kinase Assay, PromegaGmbH, Germany, #V9102)) was added, mixed and incubated for 120 min at room temperature. After the incubation period, 5 microL of ADP Glo reagent (Ready-to-use, ADP Glo Kinase Assay, Promega GmbH, Germany, #V9102) was added, mixed and incubated for 40 min at room temperature. In the last step, 10 microL of ADP Glo detection reagent (ready-to-use, ADP Glo Kinase Assay, Promega GmbH, Germany, #V9102) was added, mixed and incubated for 30 min at room temperature. For readout, a GloMax Discover GM3000 Reader (Promega GmbH, Germany, 9700000249) was used. Inhibitor concentrations were plotted against luminescence and IC50s were determined using XLFit5.5 (IDBS, Guilford) and fitted to sigmoidal dose-response curves with variable slope.

[0291] CDK9 / T1 ADPGlo activity of the compounds in the above examples: IC50<20nM: #126, #127, #128, #129, #100, #101, #103, #104, #116, #117, #118, #119, #89 , #92, #95, #133, #134, #135, #70, #107, #108, #109, #110, #138, #141, #144, #145, #146. IC50<200nM: #130, #66, #67, #68, #96, #97, #99, #102, #120, #88, #93, #94, #131, #1 32, #71, #74, #76, #77, #111, #112, #80, #81, #83, #87, #45, #124, #125, #139, #140. IC50<1000nM: #62, #65, #98, #12, #14, #115, #73, #8, #113, #16, #17, #82, #20, #22, #84 , #23, #24, #25, #26, #27, #28, #29, #32, #34, #36, #37, #38, #39, #42, #43, #46, #54, #59.

[0292] CDK2 inhibitory activity The CDK2 inhibitory activity of the compounds of the present invention was measured in combination with different cytokines and assay systems. The SelectScreen™ assessment of kinase inhibitory activity of CDK2 data points was performed twice and averaged data are reported here. The ability of the compounds of the present invention to inhibit CDK2 in a dose-dependent manner was examined using 10 inhibitor concentrations, ranging from 10 micromolar to 0.5 nM in semi-logarithmic steps, using the SelectScreen™ Kinase Inhibitor Assay Service (Invitrogen Ltd., Paisley, UK). Inhibitor concentrations were plotted against percent inhibition or percent displacement, and IC50 was determined using XLFit5.5 (IDBS, Guildford) and fitted to a sigmoidal dose-response curve with variable slope.

[0293] CDK2 / Cyclin A1 LanthaScreen activity of the compounds of the above examples: IC50<200nM: #108, #126, #128, #110. IC50<1000nM: #89, #124, #109. CDK2 / Cyclin A Z'-LYTE activity of the compounds of the above examples: IC50<200nM:#108,#126. IC50<1000nM: #128, #110, #89, #124, #109. CDK2 / Cyclin E1 LanthaScreen activity of the compounds of the above examples: IC50<200nM: #108, #126, #128, #110, #124, #89, #109. CDK2 / Cyclin A1 LanthaScreen activity of the compounds of the above examples: IC50<20nM:#108. IC50<200nM: #128, #110, #126, #89, #124, #109.

Claims

1. A compound of formula (I) or a salt thereof. 【Chemistry 1】 {During the ceremony, R 1 is an alkyl group, an alkenyl group, an alkynyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkylcycloalkyl group, a heteroalkylcycloalkyl group, an aryl group, a heteroaryl group, an aralkyl group, or a heteroaralkyl group; all of these groups may be optionally substituted; R 2 is selected from the following groups: 【Chemistry 2】 (In the formula, X is a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; X1 is a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, or heteroalkylcycloalkyl group; Y is a halogen atom, CN, OH, NH 2 , N 3 or a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, aryl, or aralkyl group; or a carbon or nitrogen atom of an optionally substituted heterocycloalkyl or heteroaryl group; or a carbon, nitrogen, oxygen, or sulfur atom of an optionally substituted heteroalkyl, heteroalkylcycloalkyl, or heteroaralkyl group; Y1 is an oxygen atom, a sulfur atom, NH; or a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl or alkylcycloalkyl group; or a carbon or nitrogen atom of an optionally substituted heteroalkyl or heteroalkylcycloalkyl group; Z and Z2 are carbon atoms of an optionally substituted alkyl group, alkenyl group, alkynyl group, cycloalkyl group, alkylcycloalkyl group, aryl group, or aralkyl group; or carbon atoms or nitrogen atoms of an optionally substituted heterocycloalkyl group or heteroaryl group; or carbon atoms, nitrogen atoms, oxygen atoms, or sulfur atoms of an optionally substituted heteroalkyl group, heteroalkylcycloalkyl group, or heteroaralkyl group; Z1 is a carbon atom of an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, or alkylcycloalkyl group; or a carbon or nitrogen atom of an optionally substituted heteroalkyl or heteroalkylcycloalkyl group; or X and Z, or X and Z1, or X and Z2, or X1 and Z, or X1 and Z1 are both part of a ring of a cycloalkyl or heterocycloalkyl group, or X and Z, or X1 and Z1 are both part of a ring of an aryl or heteroaryl group; where X is a carbon atom, X1 is a carbon atom, Z is a carbon, nitrogen, oxygen or sulfur atom, Z1 is a carbon or nitrogen atom, and Z2 is a carbon, nitrogen, oxygen or sulfur atom; R 3 is a hydrogen atom, a halogen atom, a CN group, or an alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; all of these groups may be optionally substituted; R 4 is a hydrogen atom, a halogen atom, a CN group, or an alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; all of which groups may be optionally substituted; or R 3 and R 4 together form a fused cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; all of which groups may be optionally substituted.

2. R 2 The compound of claim 1 , wherein is selected from the following group: 【Chemistry 3】 (In the formula, X and Z, or X and Z1, or X and Z2, or X1 and Z, or X1 and Z1 are both part of a ring of a cycloalkyl group or a heterocycloalkyl group, or X and Z, or X1 and Z1 are both part of a ring of an aryl group or a heteroaryl group; where X is a carbon atom, X1 is a carbon atom, Z is a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom, Z1 is a carbon atom or a nitrogen atom, and Z2 is a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom.

3. R 2 The compound of claim 1 , wherein: 【Chemistry 4】 wherein X and Z are both part of a ring of an aryl or heteroaryl group; where X is a carbon atom and Z is a carbon, nitrogen, oxygen, or sulfur atom.

4. R 2 The compound of claim 1 , wherein: 【Chemistry 5】 (wherein X1 and Z1 are both part of a ring of an aryl or heteroaryl group; where X1 is a carbon atom and Z1 is a carbon atom).

5. A compound according to any one of claims 1 to 4, wherein Y is a halogen atom, preferably Y is F or Cl.

6. R 2 is a phenyl group having one substituent in the ortho position and optionally further substituted; or a heteroaryl group containing 5 or 6 ring atoms independently selected from C, N, O and S, which heteroaryl group has one substituent in the ortho position and optionally further substituted.

7. R 2 2. The compound of claim 1, wherein is an optionally further substituted phenyl group having one substituent at the ortho position.

8. R 2 is a phenyl group bearing one substituent at the ortho position and optionally further substituted with one or two substituents; wherein the substituents are independently selected from F, Cl, Br and Me.

9. R 2 2. The compound of claim 1, wherein: is a phenyl group substituted at the 2- and 6-positions; wherein the substituents are preferably independently selected from F and Cl.

10. R 2 The compound of claim 1 , wherein is selected from the following group: 【Chemistry 6】

11. R 2 The compound according to claim 1, wherein is a 2,6-difluorophenyl group.

12. R 4 is a hydrogen atom, a halogen atom, C 1~4 Alkyl group or C 3~5 The compound according to any one of claims 1 to 11, which is a cycloalkyl group.

13. R 4 The compound according to any one of claims 1 to 12, wherein is hydrogen, a methyl group or a cyclopropyl group.

14. R 4 The compound according to any one of claims 1 to 13, wherein is hydrogen.

15. R 3 is a hydrogen atom, a halogen atom, CN, C 1~4 Alkyl group, C 1~4 The compound of any one of claims 1 to 14, which is a heteroalkyl group or an optionally substituted phenyl group.

16. R 3 is hydrogen, Cl, Br, CF 3 , CN, a methyl group, an ethyl group, an isopropyl group, or a phenyl group.

17. R 3 is Cl, R 4 The compound according to any one of claims 1 to 16, wherein is hydrogen.

18. R 3 and R 4 Both of the formula -(CH 2 ) n - group, where n is 3 or 4, in particular n is 3.

19. R 1 is optionally substituted C 3~7 19. The compound of any one of claims 1 to 18, which is a cycloalkyl group, an optionally substituted heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N, and O, an optionally substituted phenyl group, an optionally substituted benzyl group, an optionally substituted heteroaryl group containing 5 or 6 ring atoms independently selected from C, N, O, and S, or an optionally substituted heteroalkyl group containing 1 to 12 carbon atoms and 1 to 6 heteroatoms selected from N, O, and S.

20. R 1 The compound according to any one of claims 1 to 19, wherein is selected from the group consisting of: 【Chemistry 7】 (In the formula, R 5 is -NH 2 Group, C 1~6 a heteroalkyl group or a heterocycloalkyl group containing 5 or 6 ring atoms independently selected from C, N, and O; R 6a is hydrogen, halogen or C 1~4 Heteroalkyl groups (especially -O-C 1~4 alkyl group); R 6b is hydrogen, halogen or C 1~4 Heteroalkyl groups (especially -O-C 1~4 alkyl group), R 6 is C 1~6 Alkyl group, C 1~6 Heteroalkyl groups, optionally substituted C 3~7 a cycloalkyl group or a heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N, and O and which is optionally substituted; R 7a is hydrogen, halogen, CN or -O-C 1~4 is an alkyl group; R 7b is hydrogen, halogen, CN or -O-C 1~4 is an alkyl group, R 7 is C 1~6 a heteroalkyl group, an optionally substituted heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N, and O, or an optionally substituted heteroalkylcycloalkyl group containing 4 to 12 atoms independently selected from C, N, and O.

21. R 5 But -NH 2 , -NMe 2 , optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted morpholinyl, -NH(CH 2 ) 2 F, -NH(CH 2 ) 3 F, -NH(CH 2 ) 2 OH, -NH(CH 2 ) 3 OH, -NH(CH 2 ) 2 OMe, -NH(CH 2 ) 3 OMe, -N(Me)(CH 2 ) 2 F, -N(Me)(CH 2 ) 3 F, -N(Me)(CH 2 ) 2 OH, -N(Me)(CH 2 ) 3 OH, -N(Me)(CH 2 ) 2 -OMe, and -N(Me)(CH 2 ) 3 OMe; or R 6a is hydrogen, Cl or OMe, and / or R 6b is hydrogen, and / or R 6 is a methyl group, a group of formula -C(CH 3 ) 2 CN, an optionally substituted cyclohexyl group, an optionally substituted piperazinyl group, an optionally substituted piperidinyl group, or an optionally substituted tetrahydropyranyl group; or R 7b is hydrogen or a methoxy group, and / or R 7a is hydrogen, fluorine, CN or O—C 1~4 and / or R 7 is an optionally substituted piperazinyl group, an optionally substituted piperidinyl group, an optionally substituted morpholinyl group, or an optionally substituted tetrahydropyridinyl group.

22. R 6 is represented by the formula -Cy-L-R 6c where Cy is an optionally substituted C 3~7 is a cycloalkylene group or an optionally substituted heterocycloalkylene group containing 3 to 7 ring atoms independently selected from C, N, and O; L is a bond or CH 2 group, R 6c is an optionally substituted C 3~7 a cycloalkyl group or a heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N, and O, and which is optionally substituted; or R 7 is represented by the formula -Cy'-L'-R 7c where Cy′ is an optionally substituted C 3~7 is a cycloalkylene group or an optionally substituted heterocycloalkylene group containing 3 to 7 ring atoms independently selected from C, N, and O; L' is a bond or CH 2 group, R 7c is an optionally substituted C 3~7 22. The compound of claim 20 or 21, which is a cycloalkyl group or a heterocycloalkyl group containing 3 to 7 ring atoms independently selected from C, N and O and which is optionally substituted.

23. A compound according to any one of claims 1 to 22, excluding the following compounds: 【Chemistry 8】

24. 2-(2,6-difluorophenyl)-N-(3-ethoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-dichlorophenyl)-N-(3-ethoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-dichlorophenyl)-N-(3-ethoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(3-ethoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-chloro-6-fluorophenyl)-N-(3,3-dimethyl-2,3-dihydrobenzofuran-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-chloro-6-fluorophenyl)-N-(3-ethoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-chloro-6-fluorophenyl)-N-(3-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-dichlorophenyl)-N-(3-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-dichlorophenyl)-N-(3,3-dimethyl-2,3-dihydrobenzofuran-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(3-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(3,3-dimethyl-2,3-dihydrobenzofuran-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-(2,2,2-trifluoroethyl)benzamide; N-(tert-butyl)-4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)benzamide; 4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-ethylbenzamide; 4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-(tetrahydro-2H-pyran-4-yl)benzamide; 4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-(2,2,2-trifluoroethyl)benzamide; N-(tert-butyl)-4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)benzamide; 4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-ethylbenzamide; 4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-N-(tetrahydro-2H-pyran-4-yl)benzamide; N-(4-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-3-ethoxyphenyl)-2-(2,6-dichlorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(4-(1-cyclopropylpiperidin-4-yl)-3-ethoxyphenyl)-2-(2,6-dichlorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-chloro-6-fluorophenyl)-N-(3-ethoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-chloro-6-fluorophenyl)-N-(4-(1-cyclopropylpiperidin-4-yl)-3-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-chloro-6-fluorophenyl)-N-(4-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-3-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)-2-methylpropanenitrile; 2-(4-((2-(2-chloro-6-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-1H-pyrazol-1-yl)-2-methylpropanenitrile; 2-(2,6-difluorophenyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 1-(4-(4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)piperazin-1-yl)ethan-1-one; 2-(2,6-difluorophenyl)-N-(3-fluoro-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(3-methoxy-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 5-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-2-morpholinobenzonitrile; 2-(2,6-difluorophenyl)-N-(4-(4-morpholinopiperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(3-isopropoxy-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(4-(4-(tert-butyl)piperazin-1-yl)phenyl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(4-((2S,6R)-2,6-dimethylmorpholino)-3-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(3-isopropoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-fluorophenyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-fluorophenyl)-N-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 1-(4-(4-((2-(2-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)piperazin-1-yl)ethan-1-one; N-(3-fluoro-4-morpholinophenyl)-2-(2-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(4-(4-(tert-butyl)piperazin-1-yl)phenyl)-2-(2-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-fluorophenyl)-N-(3-methoxy-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 5-((2-(2-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-2-morpholinobenzonitrile; 2-(2-fluorophenyl)-N-(4-(4-morpholinopiperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-fluorophenyl)-N-(3-isopropoxy-4-morpholinophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-fluorophenyl)-N-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-fluorophenyl)-N-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-fluorophenyl)-N-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(2-(1H-pyrazol-1-yl)benzyl)-8-bromo-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(3,4-dimethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(1-(1'-methyl-[1,4'-bipiperidin]-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(1-((1r,4r)-4-morpholinocyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(2-(1H-pyrazol-1-yl)benzyl)-7-cyclopropyl-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-chloro-6-fluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 7-cyclopropyl-2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(5-chloro-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(3-chloro-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2-chloro-6-fluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-8-methyl-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-8,9-dihydro-7H-cyclopenta[3,4]pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-7-methyl-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(1-(1-(cyclopropylmethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(1-(1-(2-fluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; Methyl-4-(4-((2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate; N-(1-(1-cyclopropylpiperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(1-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(1-(1-(but-3-en-1-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-4-((1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile; 8-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-8-phenyl-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)-8-phenylpyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-4-(((1r,4r)-4-morpholinocyclohexyl)amino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile; 8-bromo-2-(2,6-difluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-bromo-2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-(1-(1'-methyl-[1,4'-bipiperidin]-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(4-(4-(tert-butyl)piperazin-1-yl)phenyl)-8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; (4-((8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)(morpholino)methanone; 8-chloro-N-(1-(1-cyclopropylpiperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-N-(1-(1-(cyclopropylmethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2-chloro-6-fluorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-dichlorophenyl)-N-(1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-(1-methyl-1H-imidazol-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-((4-((8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)pentyl)(ethyl)amino)ethan-1-ol; (1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclohexane-1,4-diamine; (1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine; 8-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(piperidin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-N-((1r,4r)-4-morpholinocyclohexyl)-8-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; (1s,4s)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclohexane-1,4-diamine; 8-chloro-2-(2,6-difluorophenyl)-N-((1s,4s)-4-(piperidin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; (1s,4s)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine; 2-(2,6-difluorophenyl)-N-(1-methyl-1H-pyrazol-4-yl)-8-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; (1R,3R)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclopentane-1,3-diamine; N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclopentane-1,3-diamine; (1r,4r)-N1-(2-(2,6-difluorophenyl)-8-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclohexane-1,4-diamine; (1R,3R)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N3,N3-dimethylcyclopentane-1,3-diamine; (1r,4r)-N1-(2-(2,6-difluorophenyl)-8-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine; (1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4-(2-methoxyethyl)cyclohexane-1,4-diamine; (1S,3R)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclopentane-1,3-diamine; (1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4-(2-fluoroethyl)cyclohexane-1,4-diamine; 2-(((1r,4r)-4-((8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)cyclohexyl)amino)ethan-1-ol; (1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4-(3-fluoropropyl)cyclohexane-1,4-diamine; (1r,3r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)cyclobutane-1,3-diamine; (1r,3r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N3,N3-dimethylcyclobutane-1,3-diamine; (1r,4r)-N1-(8-chloro-2-(2,4,6-trifluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine; (1r,4r)-N1-(8-chloro-2-(2,6-difluoro-4-methylphenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine; 2-(((1r,4r)-4-((8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)cyclohexyl)(methyl)amino)ethan-1-ol; 3-({4-[8-chloro-2-(2,6-difluoro-phenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-ylamino]-cyclohexyl}-methyl-amino)-propan-1-ol; (1r,4r)-N1-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)-N4-(3-fluoropropyl)-N4-methylcyclohexane-1,4-diamine; 8-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(pyrrolidin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-8-ethynyl-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 2-(2,6-difluorophenyl)-8-iodo-N-((1r,4r)-4-morpholinocyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-(1-methylpiperidin-4-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; N-(8-chloro-2-(2,6-difluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)quinuclidin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-((1s,4s)-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-((1r,4r)-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; 8-chloro-2-(2,6-difluorophenyl)-N-((4,6-dimethylpyridin-3-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine; and A compound selected from 8-chloro-2-(2,6-difluorophenyl)-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine.

25. 25. A salt of the compound of claim 24.

26. A pharmaceutical composition comprising a compound or salt according to any one of claims 1 to 25, and optionally one or more carrier substances and / or one or more adjuvants.

27. Diseases in which aberrant CDK, particularly CDK9 and / or CDK2, regulation is observed, such as a wide range of cytokine-induced inflammatory diseases and autoimmune diseases, local or systemic viral infections, viral infections of the eye, viral respiratory infections, or viral infections of the central and / or peripheral nervous system caused by DNA and / or RNA viruses, as well as various non-solid and solid malignancies, cancers, or hyperproliferative diseases, such as acute myeloid leukemia, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute mixed leukemia, high-grade MYC-driven B-cell lymphoma, primary peritoneal carcinoma, Kaposi's sarcoma, advanced breast cancer, non-small cell lung cancer, colorectal cancer, or liver cancer, such as hepatocellular carcinoma, cervical intraepithelial neoplasia, prostate cancer, melanoma, glioma, glioblastoma, neuroblastoma, astrocytoma, anaplastic astrocytoma, or glioblastoma, such as 27. A compound or salt according to any one of claims 1 to 25 or a pharmaceutical composition according to claim 26 for use in the treatment of, for example, progressive and / or metastatic hematological / solid malignancies, in particular for use in the treatment of hematological malignancies or solid tumours caused by aberrant expression of MYC- or MCL-1; or for use as a modulator of the immune response, as well as for use in the treatment and / or prevention of mechanical / trauma-induced inflammation, such as post-traumatic osteoarthritis (PTOA), systemic and local cytokine-induced inflammatory diseases, such as inflammatory diseases of the gastrointestinal or urinary tract, and ocular inflammatory diseases, such as Sjogren's disease and glaucoma, bacterial-induced inflammatory diseases, such as gingivitis, periodontitis; and for use in the treatment and / or prevention of cardiovascular diseases, such as cardiac hypertrophy, dilated cardiomyopathy, atherosclerosis, and cardiometabolic diseases, such as obesity and diabetes.

28. Diseases in which abnormal CDK, particularly CDK9 and / or CDK2 regulation is observed, such as a wide range of cytokine-induced inflammatory diseases and autoimmune diseases, local or systemic viral infections, viral infections of the eye, viral respiratory infections, or viral infections of the central and / or peripheral nervous system caused by DNA and / or RNA viruses, as well as various non-solid and solid malignancies, cancers, or hyperproliferative tumors. Diseases such as acute myeloid leukemia, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute mixed leukemia, high-grade MYC-driven B-cell lymphoma, primary peritoneal carcinoma, Kaposi's sarcoma, advanced breast cancer, non-small cell lung cancer, colorectal cancer, or liver cancer such as hepatocellular carcinoma, cervical intraepithelial neoplasia, prostate cancer, melanoma, glioma, glioblastoma, neuroblastoma, astrocytoma, anaplastic astrocytoma, or glioblastoma, e.g., advanced and 27. Use of a compound or salt according to any one of claims 1 to 25, or a pharmaceutical composition according to claim 26, for the preparation of a medicament for use in the treatment of chronic, chronic and / or metastatic hematological / solid malignancies, in particular for use in the treatment of hematological malignancies or solid tumors caused by aberrant expression of MYC- or MCL-1; or for use as a modulator of the immune response, as well as for the treatment and / or prevention of mechanical / trauma-induced inflammation, such as post-traumatic osteoarthritis (PTOA), systemic and local cytokine-induced inflammatory diseases, such as inflammatory diseases of the gastrointestinal or urinary tract, and ocular inflammatory diseases, such as Sjogren's disease and glaucoma, bacterial-induced inflammatory diseases, such as gingivitis, periodontitis; and for the treatment and / or prevention of cardiovascular diseases, such as cardiac hypertrophy, dilated cardiomyopathy, atherosclerosis, and cardiometabolic diseases, such as obesity and diabetes.

29. A method for the treatment of diseases in which abnormal CDK, in particular CDK9 and / or CDK2 regulation is observed, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound or salt according to any one of claims 1 to 25 or a pharmaceutical composition according to claim 26.

30. The diseases include a wide range of cytokine-induced inflammatory and autoimmune diseases, local or systemic viral infections, viral infections of the eye, viral respiratory infections, or viral infections of the central and / or peripheral nervous system caused by DNA and / or RNA viruses, as well as various non-solid and solid malignancies, cancers, or hyperproliferative diseases, such as acute myeloid leukemia, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute mixed leukemia, high-grade MYC-driven B-cell lymphoma, primary peritoneal carcinoma, Kaposi's sarcoma, advanced breast cancer, non-small cell lung cancer, colorectal cancer, or liver cancer such as hepatocellular carcinoma, cervical intraepithelial neoplasia, prostate cancer, black blood cell tumors, and ovarian cancer.

30. The method of claim 29, wherein the inflammation is selected from: tumors, gliomas, glioblastomas, neuroblastomas, astrocytomas, anaplastic astrocytomas, or glioblastomas, such as progressive and / or metastatic hematological / solid malignancies (in particular hematological malignancies or solid tumors caused by aberrant expression of MYC- or MCL-1); or mechanical / trauma-induced inflammation, such as post-traumatic osteoarthritis (PTOA), systemic and local cytokine-induced inflammatory diseases, such as inflammatory diseases of the gastrointestinal or urinary tract, and ocular inflammatory diseases, such as Sjogren's disease and glaucoma, bacterial-induced inflammatory diseases, such as gingivitis, periodontitis, and cardiovascular diseases, such as cardiac hypertrophy, dilated cardiomyopathy, atherosclerosis, and cardiometabolic diseases, such as obesity and diabetes.

31. A method for modulating an immune response, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 25 or a salt thereof, or a pharmaceutical composition according to claim 26.

32. A compound of formula (II). 【Chemistry 9】 (In the formula, R 2 , R 3 and R 4 is as defined in any one of claims 1 to 18.

33. A method for synthesizing a compound of formula (II) according to claim 32, comprising reacting a compound of formula (III) with a compound of formula H 3 with a compound of the formula C-S-C≡N. 【Chemistry 10】 (In the formula, R 2 , R 3 and R 4 is as defined in any one of claims 1 to 18.

Citation Information

Patent Citations

  • Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

    WO2008130570A1

  • Inhibitors of cyclin-dependent kinases

    WO2016160617A2